

=> d his

(FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006

L1 STRUCTURE UPLOADED  
L2 0 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006  
L3 47 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006

L4 83 S L3  
L5 77 S L4 AND 1800<=PY<=2001

FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006

L6 0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)  
L7 0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006

L8 STRUCTURE UPLOADED  
L9 50 S L8 SSS SAM  
L10 9805 S L8 SSS FULL

FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006

L11 9054 S L10  
L12 0 S L11 AND L5  
L13 0 S L11 AND L4  
L14 6 S L10 AND CHROMENE  
L15 490 S L10 AND KINASE  
L16 94 S L10 AND TYROSINE KINASE  
E MUJICA F/AU 25  
L17 6 S (E5 OR E6)  
E BUCHHOLZ H/AU 25  
L18 148 S (E3 OR E4 OR E5 OR E6 OR E19 OR E20 OR E21)  
E CAROLA C/AU 25  
L19 37 S (E3 OR E5)  
E RAUTENBERG W/AU 25  
L20 49 S (E3 OR E5 OR E7)  
E SURREBBERG C/AU 25  
E SIRREBERG C/AU 25  
L21 33 S (E4)  
L22 333 S L16 OR L17 OR L18 OR L19 OR L20 OR L21  
L23 131 S L22 AND KINASE  
L24 18 S L23 AND CHROM?  
L25 0 S L24 AND L4  
L26 0 S L23 AND L4

FILE 'STNGUIDE' ENTERED AT 18:12:57 ON 19 DEC 2006

FILE 'STNGUIDE' ENTERED AT 18:39:05 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 18:51:46 ON 19 DEC 2006

L27 1300 S FLAVANOID?  
L28 288351 S KINASE  
L29 14 S L27 AND L28  
L30 42816 S TYROSINE KINASE  
L31 3 S L30 AND L29  
L32 2 F STNG



FILE 'STNGUIDE' ENTERED AT 18:53:55 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 18:55:11 ON 19 DEC 2006

FILE 'STNGUIDE' ENTERED AT 18:58:47 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 18:59:14 ON 19 DEC 2006

L33 122622 S OXAL?  
L34 20 S L33 AND L16  
L35 3 S L33 AND L17  
L36 11 S L33 AND L5

FILE 'STNGUIDE' ENTERED AT 19:00:52 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 19:10:49 ON 19 DEC 2006

L37 STRUCTURE UPLOADED  
L38 50 S L37 SSS SAM

FILE 'STNGUIDE' ENTERED AT 19:11:59 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 19:15:58 ON 19 DEC 2006

L39 STRUCTURE UPLOADED  
L40 50 S L39 SSS SAM

FILE 'STNGUIDE' ENTERED AT 19:17:00 ON 19 DEC 2006

FILE 'STNGUIDE' ENTERED AT 19:29:06 ON 19 DEC 2006



$\geq$ 

The image displays several chemical structures, including aromatic rings and a complex molecule, with atom numbering and labels.

**Top Left:** A pyridine ring with atom 7 at the nitrogen position.

**Top Right:** A pyridine ring with atom 7 at the nitrogen position. Atoms 59, 60, 61, 62, and 58 are numbered on the ring.

**Second Row Left:** A pyridine ring with atom 1 at the nitrogen position.

**Second Row Right:** A pyridine ring with atom 1 at the nitrogen position. Atoms 8, 9, 10, and 11 are numbered on the ring.

**Third Row Left:** A pyridine ring with atom 2 at the nitrogen position.

**Third Row Right:** A pyridine ring with atom 1 at the nitrogen position. Atoms 14, 15, 16, and 17 are numbered on the ring.

**Fourth Row Left:** A pyridine ring with atom 3 at the nitrogen position. A *t*-Bu group is attached to the ring.

**Fourth Row Right:** A pyridine ring with atom 1 at the nitrogen position. Atoms 21, 22, 23, 24, 25, and 26 are numbered on the ring.

**Fifth Row Left:** A pyridine ring with atom 4 at the nitrogen position. A *t*-Bu group is attached to the ring.

**Fifth Row Right:** A pyridine ring with atom 1 at the nitrogen position. Atoms 28, 29, 30, 31, 32, and 33 are numbered on the ring.

**Sixth Row Left:** A pyridine ring with atom 5 at the nitrogen position.

**Sixth Row Right:** A pyridine ring with atom 1 at the nitrogen position. Atoms 37, 38, 39, 40, 41, and 42 are numbered on the ring.

**Seventh Row Left:** A pyridine ring with atom 6 at the nitrogen position. A *t*-Bu group is attached to the ring.

**Seventh Row Right:** A pyridine ring with atom 1 at the nitrogen position. Atoms 51, 52, 53, 54, 55, and 56 are numbered on the ring.

**Bottom Left:** A complex molecule consisting of a pyridine ring connected to a benzene ring, which is further connected to a pyridine ring. The pyridine ring on the right has atom 67 at the nitrogen position. The benzene ring has atoms 45, 46, 47, 48, 49, and 50 numbered. The pyridine ring on the left has atoms 1, 2, 3, 4, 5, and 6 numbered.

25    32    48    55    67

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 19 20 21 22 23 24

58    59    60    61    62

2-42    4-67    23-25    30-32    44-48    53-55

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15

35-36 35-40 36-37 37-38 38-39 39-40 42-43 42-47 43-44 44-45 45-46 46-47 49-50 49-54

50-51   51-52   52-53   53-54   57-58   57-62   58-59   59-60   60-61   61-62

1-2 1-5 2-3 3-4 4-5 4-67 42-43 42-47 43-44 44-45 44-48 45-46 46-47

2-42    23-25    30-32    53-55

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17 19-20  
19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28 28-29 29-30 30-31 35-36 35-40 36-  
37  
37-38 38-39 39-40 49-50 49-54 50-51 51-52 52-53 53-54 57-58 57-62 58-59 59-60 60-  
61  
61-62

G1:Ph,o-C6H4,m-C6H4,p-C6H4,PhO,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,[\*1],[\*2],[\*3],[  
\*4],[\*5],[\*6],[\*7]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom 20:Atom 21:Atom  
22:Atom  
23:Atom 24:Atom 25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS  
35:Atom  
36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom  
47:Atom  
48:CLASS 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom 55:CLASS 57:Atom 58:Atom  
59:Atom  
60:Atom 61:Atom 62:Atom 67:CLASS

L1 STRUCTURE UPLOADED

=> d l1 sss sam

L1 HAS NO ANSWERS

'SSS SAM' IS NOT A VALID STRUCTURE FORMAT KEYWORD

Structure Formats

SIA ----- Structure Image, Attributes, and map table if it contains  
data. (Default)

SIM ----- Structure Image.

SAT ----- Structure ATtributes and map table if it contains data.

SCT ----- Structure Connection Table and map table if it contains  
data.

SDA ----- All Structure DATA (image, attributes, connection table and  
map table if it contains data).

NOS ----- NO Structure data.

ENTER STRUCTURE FORMAT (SIM), NOS:.

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:14:52 FILE.'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 87 TO ITERATE

100.0% PROCESSED 87 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1181 TO 2299  
PROJECTED ANSWERS: 0 TO 0

L2 0. SEA SSS SAM L1

=> s l1 sss full  
FULL SEARCH INITIATED 14:15:04 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1512 TO ITERATE

100.0% PROCESSED 1512 ITERATIONS 3 ANSWERS  
SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1

=> fil hcaplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 167.38 167.59

FILE 'HCAPLUS' ENTERED AT 14:15:15 ON 19 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26  
FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3  
L4 1 L3

=> d l4 ibib abs hitstr

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:470326 HCAPLUS Full-text  
DOCUMENT NUMBER: 141:38618  
TITLE: Preparation of oxadiazolylchromones as modulators of tyrosine kinase signal transduction.  
INVENTOR(S): Mujica-Fernaund, Teresa; Buchholz, Herwig; Carola, Christophe; Rautenberg, Wilfried; Sirrenberg, Christian  
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
SOURCE: Eur. Pat. Appl., 33 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1426372	A1	20040609	EP 2003-26103	20031113
EP 1426372	B1	20060111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
DE 10256182	A1	20040624	DE 2002-10256182	20021202
AT 315564	T	20060215	AT 2003-26103	20031113
ES 2255654	T3	20060701	ES 2003-3026103	20031113
US 2004138464	A1	20040715	US 2003-725346	20031202
PRIORITY APPLN. INFO.:			DE 2002-10256182	A 20021202
OTHER SOURCE(S):	MARPAT 141:38618			
GI				



AB Title compds. [I; R = A, pyridyl, (substituted) Ph; X = H, OH, PhO, OA, O2CA, SO3H, OSO3H, OSO3A, halo, CO2H, CO2A, CONH2, NHSO2A, COA, CHO, SO2NH2, etc.; A = alkyl, fluoroalkyl; n = 1-4], were prepared Thus, 2,5-dihydroxyacetophenone and di-Et oxalate were heated 3 h at 80° in EtOH to give 6-hydroxy-2-ethoxycarbonylchromone. This was refluxed with aqueous HCl in HOAc to give 6-hydroxychromon-2-carboxylic acid. The latter in THF at -10° was treated with Et3N and iso-Bu chloroformate; after stirring for 1 h, 4-tert-butylbenzaloxime in THF was added followed by stirring for 30 min. at room temperature and at reflux for 90 min. to give 6-hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone. The latter inhibited Tie2 receptor tyrosine kinase with IC50 >10 µM.


IT 700813-20-3P, 6-Hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone 700813-21-4P, 7-Hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]chromone 700813-22-5P, 6-Hydroxy-2-[3-(pyridin-2-yl)-1,2,4-oxadiazol-5-yl]chromone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of oxadiazolylchromones as modulators of tyrosine kinase signal transduction)

RN 700813-20-3 HCAPLUS


CN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]-6-hydroxy- (9CI) (CA INDEX NAME)




RN 700813-21-4 HCAPLUS

CN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]-7-hydroxy- (9CI) (CA INDEX NAME)





RN 700813-22-5 HCAPLUS  
 CN 4H-1-Benzopyran-4-one, 6-hydroxy-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-  
 (9CI) (CA INDEX NAME)



=> fil stng

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.64	175.23

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.75	-0.75

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 14:16:05 ON 19 DEC 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
 AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
 LOGOFF? (Y)/N/HOLD:n

=> d his

(FILE 'HOME' ENTERED AT 14:13:50 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 14:13:57 ON 19 DEC 2006

L1 STRUCTURE UPLOADED  
 L2 0 S L1 SSS SAM  
 L3 3 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 14:15:15 ON 19 DEC 2006

L4 1 S L3

FILE 'STNGUIDE' ENTERED AT 14:16:05 ON 19 DEC 2006

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
 LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION


FULL ESTIMATED COST	0.06	175.29
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

STN INTERNATIONAL LOGOFF AT 14:16:19 ON 19 DEC 2006

Connecting via Winsock to STN

=>

Uploading C:\Program Files\Stnexp\Queries\346vi.str



chain nodes :

25 32 48 55 67

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 19 20 21 22 23 24

26 27 28 29 30 31 35 36 37 38 39 40 42 43 44 45 46 47 49 50 51 52 53 54 57

58 59 60 61 62

chain bonds :

4-67 23-25 30-32 44-48 53-55

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15

15-16 16-17 19-20 19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28 28-29 29-30 30-31

35-36 35-40 36-37 37-38 38-39 39-40 42-47 42-43 43-44 44-45 45-46 46-47 49-50 49-54

50-51 51-52 52-53 53-54 57-58 57-62 58-59 59-60 60-61 61-62

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 4-67 23-25 30-32 42-47 42-43 43-44 44-45 44-48 45-46

46-47 53-55

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17 19-20

19-24 20-21 21-22 22-23 23-24 26-27 26-31 27-28 28-29 29-30 30-31 35-36 35-40 36-

37  
37-38 38-39 39-40 49-50 49-54 50-51 51-52 52-53 53-54 57-58 57-62 58-59 59-60 60-  
61  
61-62

G1:Ph,o-C6H4,m-C6H4,p-C6H4,PhO,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,[\*1],[\*2],[\*3],[  
\*4],[\*5],[\*6],[\*7]

G2:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom 20:Atom 21:Atom  
22:Atom  
23:Atom 24:Atom 25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS  
35:Atom  
36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom  
47:Atom  
48:CLASS 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom 55:CLASS 57:Atom 58:Atom  
59:Atom  
60:Atom 61:Atom 62:Atom 67:CLASS 68:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:22:23 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 62 TO ITERATE

100.0% PROCESSED 62 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 768 TO 1712

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l2 sss full

FULL SEARCH INITIATED 14:22:38 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1078 TO ITERATE

100.0% PROCESSED 1078 ITERATIONS

12 ANSWERS

SEARCH TIME: 00.00.01

L3 12 SEA SSS FUL L1


=> d scan

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN D-Glucitol, 1,5-anhydro-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]-,  
2,3,4,6-tetrabenzoate, (1R)-(9CI)

MF C42 H31 N3 O12

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):12

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)-(9CI)  
MF C14 H14 N2 O5


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN D-Glucitol, 1,5-anhydro-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-, 2,3,4,6-tetrabenzoate, (1R)-(9CI)  
MF C43 H34 N2 O11


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN D-Glucitol, 1,5-anhydro-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]-,  
(1R)-(9CI)  
MF C14 H15 N3 O8

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]-7-hydroxy- (9CI)  
MF C21 H18 N2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN D-Glucitol, 1,5-anhydro-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-,  
(1R)-(9CI)  
MF C15 H18 N2 O7


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]- (9CI)  
MF C14 H13 N3 O7


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN D-Glucitol, 1,5-anhydro-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)-, 2,3,4,6-tetrabenzoate, (1R) - (9CI)  
MF C42 H32 N2 O10


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]- (9CI)  
MF C15 H16 N2 O6

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-4-one, 6-hydroxy-2-[3-(2-pyridinyl)-1,2,4-oxadiazol-5-yl]-  
 (9CI)  
 MF C16 H9 N3 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN D-Glucitol, 1,5-anhydro-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)-, (1R)- (9CI)  
 MF C14 H16 N2 O6


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 12 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-4-one, 2-[3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl]-6-hydroxy- (9CI)  
 MF C21 H18 N2 O4





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> fil hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

167.59

FILE 'HCAPLUS' ENTERED AT 14:22:58 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26

FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 14:21:32 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 14:21:39 ON 19 DEC 2006

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS SAM

L3 12 S L2 SSS FULL

FILE 'HCAPLUS' ENTERED AT 14:22:58 ON 19 DEC 2006

=> s l3

L4 2 L3

=> d l4 ti

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

TI 1,3-Dipolar cycloaddition reactions on carbohydrate-based templates:  
Synthesis of spiro-isoxazolines and 1,2,4-oxadiazoles as glycogen  
phosphorylase inhibitors

=> d 14 ti 2

L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of oxadiazolylchromones as modulators of tyrosine kinase signal transduction.

=> d 14 1 ibib abs hitstr

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:757596 HCAPLUS Full-text

DOCUMENT NUMBER: 145:315180

TITLE: 1,3-Dipolar cycloaddition reactions on carbohydrate-based templates: Synthesis of spiro-isoxazolines and 1,2,4-oxadiazoles as glycogen phosphorylase inhibitors

AUTHOR(S): Benltifa, Mahmoud; Vidal, Sebastien; Gueyrard, David; Goekjian, Peter G.; Msaddek, Moncef; Praly, Jean-Pierre

CORPORATE SOURCE: Laboratoire de Chimie Organique 2 - Glycochimie, UMR-CNRS 5181, CPE-Lyon, Universite Claude Bernard Lyon 1, Villeurbanne, F-69622, Fr.

SOURCE: Tetrahedron Letters (2006), 47(34), 6143-6147  
CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:315180

AB 1,3-Dipolar cycloaddn. of aryl nitrile oxides to benzyl/acetyl-protected exo-glucals and to a benzoylated glucosyl cyanide led in high yield to spiro-isoxazolines and to 3-aryl-5-glucosyl-1,2,4-oxadiazoles, resp. The choice of the protective groups was important to the outcome of the cycloaddn. and for the deprotection of the adducts. Cleavage of the ester protecting groups (acetyl, benzoyl) provided water-soluble spiro-isoxazolines and 3-aryl-5-glucosyl-1,2,4-oxadiazoles, evaluated as glycogen phosphorylase inhibitors. Preliminary tests showed IC50 values in the  $\mu$ M range.

IT 909109-15-5P 909109-16-6P 909109-17-7P


RL: BYP (Byproduct); PREP (Preparation)

(preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)

RN 909109-15-5 HCAPLUS

CN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 909109-16-6 HCAPLUS

CN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 909109-17-7 HCAPLUS

CN D-arabino-Hex-1-enitol, 1,5-anhydro-2-deoxy-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 909109-13-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)

RN 909109-13-3 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 909109-09-7P 909109-10-0P 909109-11-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)

RN 909109-09-7 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-, 2,3,4,6-tetrabenzoate, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 909109-10-0 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-(3-phenyl-1,2,4-oxadiazol-5-yl)-, 2,3,4,6-tetrabenzoate, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 909109-11-1 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]-, 2,3,4,6-tetrabenzoate, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 909109-12-2P 909109-14-4P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of spiro-isoxazolines and oxadiazoles as glycogen phosphorylase inhibitors by dipolar cycloaddn. on carbohydrates)

RN 909109-12-2 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 909109-14-4 HCAPLUS

CN D-Glucitol, 1,5-anhydro-1-C-[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

10.83	178.42
-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-0.75	-0.75
-------	-------

FILE 'STNGUIDE' ENTERED AT 14:23:58 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

0.30	178.72
------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00	-0.75
------	-------

FILE 'REGISTRY' ENTERED AT 14:26:45 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6  
DICTIONARY FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\346vii.str



chain nodes :

12

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

8-12

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-11 6-7 7-8 8-9 9-10 10-11

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 6-11 6-7 7-8 8-9 8-12 9-10 10-11

G1:Ph,o-C6H4,m-C6H4,p-C6H4,PhO,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


11:Atom 12:CLASS 15:Atom

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR



G1 Ph, O-C<sub>6</sub>H<sub>4</sub>, m-C<sub>6</sub>H<sub>4</sub>, p-C<sub>6</sub>H<sub>4</sub>, PhO, Et, n-Pr, i-Pr, n-Bu, i-Bu, s-Bu, t-Bu  
 G2 O, S

Structure attributes must be viewed using STN Express query preparation.

=> s l5 sss sam

SAMPLE SEARCH INITIATED 14:27:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 376 TO ITERATE

100.0% PROCESSED 376 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 6357 TO 8683

PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

0.44	179.16
------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00	-0.75
------	-------


STN INTERNATIONAL LOGOFF AT 14:27:27 ON 19 DEC 2006



<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\346viii.str



chain nodes :

11 12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

8-12 10-11 12-13 12-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

5-7 6-10 7-8 8-9 9-10 10-11 12-13

exact bonds :

8-12 12-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


11:CLASS 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d.l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 16:53:32 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 39 TO ITERATE

100.0% PROCESSED 39 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 406 TO 1154

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

0.88	1.09
------	------

FILE 'STNGUIDE' ENTERED AT 16:54:27 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT


COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\346ix.str



chain nodes :

11 12 13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

8-12 10-11 12-13 12-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

5-7 6-10 7-8 8-9 9-10 10-11 12-13

exact bonds :

8-12 12-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


11:CLASS 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 17:32:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 19 TO ITERATE

100.0% PROCESSED 19 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 119 TO 641  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	0.65

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> s l1 sss full

SUBSTANCE QUERIES NOT VALID IN THIS FILE

The logic expression entered contains L#s or saved query names which correspond to structures built by the STRUCTURE command or to screen sets. These must be searched in a substance file such as the REGISTRY file. In some files you may use a Registry Number answer set from a structure search as a search term or profile in some bibliographic file containing Registry Numbers, e.g. the CA file. For an explanation, enter "HELP CROSSOVER" at an arrow prompt (=>).

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.12	0.77

FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6  
DICTIONARY FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s l1 sss full

FULL SEARCH INITIATED 17:33:26 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 291 TO ITERATE

100.0% PROCESSED 291 ITERATIONS

47 ANSWERS

SEARCH TIME: 00'00.01


L3 47 SEA SSS FUL L1

=> d scan

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo-5-(2-phenoxyethoxy) - (9CI)

MF C18 H13 Cl O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):50

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 4H-1-Benzopyran-2-carbonyl chloride, 5-hydroxy-4-oxo- (9CI)

MF C10 H5 Cl O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN


IN 4H,10H-Benzo[1,2-b:3,4-b']dipyrans-2,8-dicarbonyl dichloride, 5-hydroxy-4,10-dioxo-6-(2-propenyl) - (9CI)

MF C17 H8 Cl2 O7




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 6-fluoro-4-oxo- (9CI)  
 MF C10 H4 Cl F O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 7-methoxy-4-oxo- (9CI)  
 MF C11 H7 Cl O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-6-acrylic acid, 2-(chloroformyl)-5-hydroxy-β-methyl-4-oxo-, δ-lactone (7CI)  
 MF C14 H7 Cl O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 8-(aminocarbonyl)-7-hydroxy-4-oxo- (9CI)  
 MF C11 H6 Cl N O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 6,7-dihydroxy-4-oxo- (9CI)  
 MF C10 H5 Cl O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 7-nitro-4-oxo- (9CI)  
 MF C10 H4 Cl N O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H-1-Benzopyran-2-carbonyl chloride, 5,5'-[(2-hydroxy-1,3-  
propanediyl)bis(oxy)]bis[4-oxo- (9CI)  
MF C23 H14 Cl2 O9



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***


L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-ethoxy-8-(4-methyl-1-piperazinyl)-4-  
oxo- (9CI)  
MF C17 H19 Cl N2 O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-chloro-4-oxo- (8CI, 9CI)  
MF C10 H4 Cl2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H,10H-Benzo[1,2-b:3,4-b']dipyran-2,8-dicarbonyl dichloride,  
5-methoxy-4,10-dioxo- (9CI)  
MF C15 H6 Cl2 O7



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H,10H-Benzo[1,2-b:3,4-b']dipyran-2,8-dicarbonyl dichloride,  
6-bromo-5-hydroxy-4,10-dioxo- (9CI)  
MF C14 H3 Br Cl2 O7



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 4H-1-Benzopyran-2-carbonyl chloride, 5-(2-ethoxyethoxy)-4-oxo- (9CI)  
MF C14 H13 Cl O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-bromo-4-oxo- (9CI)  
MF C10 H4 Br Cl O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H-1-Benzopyran-2-carbonyl chloride, 3-methyl-4-oxo- (9CI)  
MF C11 H7 Cl O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 9H-Furo[2,3-f][1]benzopyran-7-carbonyl chloride, 3-methyl-9-oxo- (7CI)  
MF C13 H7 Cl O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-14C-2-carbonyl-14C chloride, 4-oxo- (9CI)  
 MF C10 H5 Cl O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 6,7-bis(acetyloxy)-4-oxo- (9CI)  
 MF C14 H9 Cl O7




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 7-fluoro-4-oxo- (9CI)  
 MF C10 H4 Cl F O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 6-(1,1-dimethylethyl)-8-nitro-4-oxo-  
 (9CI)  
 MF C14 H12 Cl N O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo-, 4-chlorocoumarin (6CI)  
 MF C10 H5 Cl O3 . C9 H5 Cl O2


CM 1



CM 2




L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 6,8-bis(1,1-dimethylethyl)-4-oxo-  
 (9CI)  
 MF C18 H21 Cl O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 5,5'-[[2-(formyloxy)-1,3-  
 propanediyl]bis(oxy)]bis[4-oxo- (9CI)  
 MF C24 H14 Cl2 O10




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H,10H-Benzo[1,2-b:3,4-b']dipyran-2,8-dicarbonyl dichloride,  
 4,10-dioxo-5-(2-propenyloxy)- (9CI)  
 MF C17 H8 Cl2 O7




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H-Naphtho[2,3-b]pyran-2-carbonyl chloride, 6,7,8,9-tetrahydro-4-oxo-10-propyl- (9CI)  
MF C17 H17 Cl O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H-1-Benzopyran-2-carbonyl chloride, 6-nitro-4-oxo- (9CI)  
MF C10 H4 Cl N O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H-Pyrano[3,2-g]quinoline-2,8-dicarbonyl dichloride, 6-chloro-4-oxo-10-propyl- (9CI)  
MF C17 H10 Cl3 N O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 4H-1-Benzopyran-2,7-dicarbonyl dichloride, 4-oxo- (9CI)  
MF C11 H4 Cl2 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 3-bromo-4-oxo- (9CI)  
 MF C10 H4 Br Cl O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 7-[(methylsulfonyl)amino]-4-oxo-6-  
 phenoxy- (9CI)  
 MF C17 H12 Cl N O6 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 7-chloro-4-oxo- (9CI)  
 MF C10 H4 Cl2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 3-methyl-4-oxo-8-(1-propenyl)- (9CI)  
 MF C14 H11 Cl O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo- (6CI, 7CI, 8CI, 9CI)  
 MF C10 H5 Cl O3  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 5-(3-methylbutoxy)-4-oxo-8-(2-propenyl)- (9CI)  
 MF C18 H19 Cl O4






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-Naphtho[2,3-b]pyran-2-carbonyl chloride, 6,7,8,9-tetrahydro-4-oxo-  
 (9CI)  
 MF C14 H11 Cl O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H,6H-Benzo[1,2-b:5,4-b']dipyran-2,8-dicarbonyl dichloride,  
 10-ethyl-4,6-dioxo- (9CI)  
 MF C16 H8 Cl2 O6




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-Naphtho[2,3-b]pyran-2-carbonyl chloride, 6,7,8,9-tetrahydro-5-hydroxy-4-  
 oxo-10-propyl- (9CI)  
 MF C17 H17 Cl O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 6-methyl-4-oxo- (9CI)  
 MF C11 H7 Cl O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 6-methyl-3-octyl-4-oxo- (9CI)  
 MF C19 H23 Cl O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2,8-dicarbonyl dichloride, 6-methyl-4-oxo- (9CI)  
 MF C12 H6 Cl2 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-Pyrano[3,2-g]quinoline-2,8-dicarbonyl dichloride, 9-ethyl-6,9-dihydro-  
 4,6-dioxo-10-propyl- (9CI)  
 MF C19 H15 Cl2 N O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 3-chloro-4-oxo- (9CI)  
 MF C10 H4 Cl2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 7-bromo-4-oxo- (9CI)  
 MF C10 H4 Br Cl O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 7-methyl-4-oxo- (9CI)  
 MF C11 H7 Cl O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 47 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 4H-1-Benzopyran-2-carbonyl chloride, 6,8-dichloro-4-oxo- (8CI)  
 MF C10 H3 Cl3 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> d his

(FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006

L3 47 S L1 SSS FULL

=> fil hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.71

FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26

FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 83 L3

=> S L4 AND 1800<=PY<=2001

21842532 1800<=PY<=2001

L5 77 L4 AND 1800<=PY<=2001

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.06

172.77

FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> d his

(FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006

L3 47 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006

L4 83 S L3  
L5 77 S L4 AND 1800<=PY<=2001

FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.90	173.67

FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26  
FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15 and ( 4H-1-Benzopyran-2-carbonyl chloride methyl oxo)

39560 4H  
8939125 1  
12178 BENZOPYRAN  
1131 BENZOPYRANS  
12576 BENZOPYRAN  
(BENZOPYRAN OR BENZOPYRANS)  
8979331 2  
171562 CARBONYL  
27462 CARBONYLS  
179753 CARBONYL  
(CARBONYL OR CARBONYLS)  
1107475 CHLORIDE  
159773 CHLORIDES  
1180706 CHLORIDE  
(CHLORIDE OR CHLORIDES)  
988977 METHYL  
668 METHYLS  
989384 METHYL  
(METHYL OR METHYLS)  
927662 ME  
10527 MES  
934211 ME  
(ME OR MES)  
1587567 METHYL  
(METHYL OR ME)  
154530 OXO  
26 OXOS  
154533 OXO  
(OXO OR OXOS)  
0 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO



FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:n

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26

FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l10

L11 9054 L10

=> d his

(FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006

L3 47 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006

L4 83 S L3

L5 77 S L4 AND 1800<=PY<=2001

FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006

L6 0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)

L7 0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006

L8 STRUCTURE UPLOADED



L9 50 S L8 SSS SAM  
L10 9805 S L8 SSS FULL

FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006

L11 9054 S L10

=> s l11 and l5

L12 0 L11 AND L5

=> s l11 and l4

L13 0 L11 AND L4

=> s l10 and chromene

9054 L10

1962 CHROMENE

885 CHROMENES

2270 CHROMENE

(CHROMENE OR CHROMENES)

L14 6 L10 AND CHROMENE

=> d l14 ibib abs hitstr

L14 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:931479 HCAPLUS Full-text

DOCUMENT NUMBER: 140:5049

TITLE: Preparation of substituted 4-aryl-4H-pyrrolo[2,3-h]  
chromenes and analogs as activators of  
caspases and inducers of apoptosis and their uses  
against cancer and other disorders

INVENTOR(S): Cai, Sui Xiong; Jiang, Songchun; Kemnitzer, William  
E.; Zhang, Hong; Attardo, Giorgio; Denis, Real

PATENT ASSIGNEE(S): Cytovia, Inc., USA; Shire Biochem, Inc.

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097806	A2	20031127	WO 2003-US15427	20030516
WO 2003097806	A3	20040930		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2484702	A1	20031127	CA 2003-2484702	20030516
AU 2003230411	A1	20031202	AU 2003-230411	20030516
EP 1509515	A2	20050302	EP 2003-724599	20030516
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1668609	A	20050914	CN 2003-816725	20030516
JP 2005531566	T	20051020	JP 2004-506465	20030516
US 2006104998	A1	20060518	US 2004-514427	20041116
PRIORITY APPLN. INFO.:			US 2002-378079P	P 20020516
			WO 2003-US15427	W 20030516

OTHER SOURCE(S): MARPAT 140:5049

GI




AB The present invention is directed to substituted 4-aryl-4H-pyrrolo[2,3-h] chromenes and analogs thereof (shown as I; variables defined below; e.g. II). The present invention also relates to the discovery that compds. I are activators of caspases and inducers of apoptosis. Therefore, I can be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. The ability to activate the caspase cascade and induce apoptosis in human breast cancer cell lines T-47D and ZR-75-1 was measured for .apprx.50 examples of I, e.g. EC50 (nM) = 2.3 and 1.6, resp., for II. Although the methods of preparation are not claimed, .apprx.50 example preps. are included. For I: R1 = alkyl, cycloalkyl, cycloalkylalkyl, hydroxyalkyl, haloalkyl, alkoxyalkyl, aminoalkyl and oxiranylalkyl; R3 and R4 = H, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C1-10 alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthio; R5 is H or C1-10 alkyl. A is (un)substituted and is aryl, heteroaryl, saturated carbocyclic, partially saturated carbocyclic, saturated heterocyclic, partially saturated heterocyclic or arylalkyl; D is (un)substituted and is a heteroarom., partially saturated (un)saturated heterocyclic fused ring, wherein said fused ring has 5 or 6 ring atoms, wherein one or two of said ring atoms are N atoms and the others of said ring atoms are C atoms. Y is CN, COR19, CO2R19 or CONR20R21, wherein R19, R20 and R21 = H, C1-10-alkyl, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl or aminoalkyl; or R20 and R21 are taken together with the N to form a heterocycle; and Z is NR22R23, NHCOR22N(COR23)2, N(COR22)(COR23), N:CHOR19 or N:CHR19 wherein R22 and R23 = H, C1-4 alkyl or aryl, or R22 and R23 are combined together with the group attached to them to form a heterocycle.

IT 127-07-1, Hydroxyurea

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(codrug; preparation of substituted 4-aryl-4H-pyrrolo[2,3-h]  
chromenes and analogs as activators of caspases and inducers of  
apoptosis and their uses against cancer and other disorders)

RN 127-07-1 HCAPLUS

CN Urea, hydroxy- (6CI, 8CI, 9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006

L1 STRUCTURE UPLOADED

```

L2          0 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006
L3          47 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006
L4          83 S L3
L5          77 S L4 AND 1800<=PY<=2001

FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006
L6          0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)
L7          0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006
L8          STRUCTURE UPLOADED
L9          50 S L8 SSS SAM
L10         9805 S L8 SSS FULL

FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006
L11         9054 S L10
L12         0 S L11 AND L5
L13         0 S L11 AND L4
L14         6 S L10 AND CHROMENE

=> s l10 and kinase
          9054 L10
          279466 KINASE
          54347 KINASES
          288351 KINASE
          (KINASE OR KINASES)
L15         490 L10 AND KINASE

=> s l10 and tyrosine kinase
          9054 L10
          155428 TYROSINE
          2627 TYROSINES
          155960 TYROSINE
          (TYROSINE OR TYROSINES)
          279466 KINASE
          54347 KINASES
          288351 KINASE
          (KINASE OR KINASES)
          42816 TYROSINE KINASE
          (TYROSINE(W) KINASE)
L16         94 L10 AND TYROSINE KINASE

=> E MUJICA F/AU 25
E1          2      MUJICA E/AU
E2          2      MUJICA EMILIA/AU
E3          0 --> MUJICA F/AU
E4          1      MUJICA FELIX DIAZ/AU
E5          1      MUJICA FERNAUD M TERESA/AU
E6          5      MUJICA FERNAUD TERESA/AU
E7          4      MUJICA G/AU
E8          1      MUJICA G AYESTARAN/AU
E9          1      MUJICA GONZALEZ MANUEL/AU
E10         1      MUJICA GUSTAVO ROJAS/AU
E11         2      MUJICA HECTOR J/AU
E12         1      MUJICA IGNACIO/AU
E13         2      MUJICA J D/AU

```

E14	1	MUJICA J L/AU
E15	3	MUJICA JIMENEZ C/AU
E16	11	MUJICA JIMENEZ CARLOS/AU
E17	1	MUJICA JOSE L/AU
E18	1	MUJICA L E/AU
E19	1	MUJICA L F/AU
E20	2	MUJICA LOPEZ K I/AU
E21	2	MUJICA LORENA/AU
E22	4	MUJICA M B/AU
E23	3	MUJICA M T/AU
E24	6	MUJICA M TERESA/AU
E25	1	MUJICA MARIA C/AU

=> S (E5 OR E6)

	1	"MUJICA FERNAUD M TERESA"/AU
	5	"MUJICA FERNAUD TERESA"/AU
L17	6	("MUJICA FERNAUD M TERESA"/AU OR "MUJICA FERNAUD TERESA"/AU)

=> E BUCHHOLZ H/AU 25

E1	3	BUCHHOLZ GUNTHER/AU
E2	2	BUCHHOLZ GUSTAV/AU
E3	56 -->	BUCHHOLZ H/AU
E4	3	BUCHHOLZ H G/AU
E5	1	BUCHHOLZ H V/AU
E6	1	BUCHHOLZ H W/AU
E7	2	BUCHHOLZ HAGEN/AU
E8	12	BUCHHOLZ HANS GEORG/AU
E9	4	BUCHHOLZ HANS VOLKER/AU
E10	2	BUCHHOLZ HARTMUT/AU
E11	1	BUCHHOLZ HEIKE/AU
E12	10	BUCHHOLZ HEINRICH/AU
E13	3	BUCHHOLZ HEINZ/AU
E14	2	BUCHHOLZ HELENE/AU
E15	1	BUCHHOLZ HERBERT/AU
E16	1	BUCHHOLZ HERBERT F/AU
E17	1	BUCHHOLZ HERMANN/AU
E18	1	BUCHHOLZ HERTHA NEE MEISENHEIMER/AU
E19	74	BUCHHOLZ HERWIG/AU
E20	12	BUCHHOLZ HERWIG A/AU
E21	1	BUCHHOLZ HERWING/AU
E22	17	BUCHHOLZ HORST/AU
E23	1	BUCHHOLZ HORZT/AU
E24	2	BUCHHOLZ HUGO/AU
E25	5	BUCHHOLZ I/AU

=> S (E3 OR E4 OR E5 OR E6 OR E19 OR E20 OR E21)

	56	"BUCHHOLZ H"/AU
	3	"BUCHHOLZ H G"/AU
	1	"BUCHHOLZ H V"/AU
	1	"BUCHHOLZ H W"/AU
	74	"BUCHHOLZ HERWIG"/AU
	12	"BUCHHOLZ HERWIG A"/AU
	1	"BUCHHOLZ HERWING"/AU
L18	148	("BUCHHOLZ H"/AU OR "BUCHHOLZ H G"/AU OR "BUCHHOLZ H V"/AU OR "BUCHHOLZ H W"/AU OR "BUCHHOLZ HERWIG"/AU OR "BUCHHOLZ HERWIG A"/AU OR "BUCHHOLZ HERWING"/AU)

=> E CAROLA C/AU 25

E1	1	CAROLA ANTONIETTA/AU
E2	1	CAROLA ARMAND/AU
E3	13 -->	CAROLA C/AU
E4	16	CAROLA CESARE/AU
E5	24	CAROLA CHRISTOPHE/AU
E6	6	CAROLA E/AU
E7	6	CAROLA ELISABETH/AU
E8	1	CAROLA EVA/AU
E9	1	CAROLA F/AU

E10	1	CAROLA FINARELLI ALBA/AU
E11	1	CAROLA JOSEPH M/AU
E12	1	CAROLA KIM V/AU
E13	1	CAROLA LANDER/AU
E14	1	CAROLA M/AU
E15	1	CAROLA MARIA/AU
E16	7	CAROLA T P G/AU
E17	1	CAROLA V/AU
E18	1	CAROLA VILLANUEVA C/AU
E19	2	CAROLAN ADRIAN/AU
E20	1	CAROLAN B M/AU
E21	5	CAROLAN C/AU
E22	1	CAROLAN C A/AU
E23	3	CAROLAN CATHERINE/AU
E24	1	CAROLAN CHRISTINA/AU
E25	1	CAROLAN D/AU

=> S (E3 OR E5)

	13	"CAROLA C"/AU
	24	"CAROLA CHRISTOPHE"/AU
L19	37	("CAROLA C"/AU OR "CAROLA CHRISTOPHE"/AU)

=> E RAUTENBERG W/AU 25

E1	2	RAUTENBERG U/AU
E2	2	RAUTENBERG UTE/AU
E3	16	--> RAUTENBERG W/AU
E4	3	RAUTENBERG WERNER/AU
E5	32	RAUTENBERG WILFRIED/AU
E6	2	RAUTENBERGER RALF/AU
E7	1	RAUTENBERGER WILFRIED/AU
E8	5	RAUTENBURG H W/AU
E9	1	RAUTENBURG P/AU
E10	1	RAUTENBUSCH W/AU
E11	1	RAUTENFELDT V/AU
E12	1	RAUTENGARTEN A M/AU
E13	2	RAUTENGARTEN CARSTEN/AU
E14	1	RAUTENGARTEN JENS/AU
E15	4	RAUTENHAUS HEINRICH/AU
E16	1	RAUTENKRANZ ANDREAS A F/AU
E17	1	RAUTENKRANZ D/AU
E18	1	RAUTENKRANZ DOUG/AU
E19	3	RAUTENSCHLEIN M/AU
E20	1	RAUTENSCHLEIN MARTINA/AU
E21	3	RAUTENSCHLEIN S/AU
E22	8	RAUTENSCHLEIN SILKE/AU
E23	1	RAUTENSHTAIN E I/AU
E24	1	RAUTENSHTAIN S M/AU
E25	2	RAUTENSHTAIN V YA/AU

=> S (E3 OR E5 OR E7)

	16	"RAUTENBERG W"/AU
	32	"RAUTENBERG WILFRIED"/AU
	1	"RAUTENBERGER WILFRIED"/AU
L20	49	("RAUTENBERG W"/AU OR "RAUTENBERG WILFRIED"/AU OR "RAUTENBERGER WILFRIED"/AU)

=> E SURREBBERG C/AU 25

E1	2	SURRE L/AU
E2	1	SURRE MICHELE/AU
E3	0	--> SURREBBERG C/AU
E4	2	SURREL FANNY/AU
E5	1	SURREL MARIE NOELLE/AU
E6	5	SURREL Y/AU
E7	4	SURREL YVES/AU
E8	2	SURRENA HARLAND J/AU
E9	1	SURRENA P S/AU
E10	1	SURRENDRANATH V/AU

E11	34	SURRENTI C/AU
E12	39	SURRENTI CALOGERO/AU
E13	3	SURRENTI E/AU
E14	4	SURRENTI ELISABETTA/AU
E15	2	SURRENTI NADIA/AU
E16	3	SURRENTINO S/AU
E17	1	SURRENTINO SANDRO/AU
E18	1	SURRETT A D/AU
E19	2	SURRETT APRIL D/AU
E20	2	SURRETT R S/AU
E21	1	SURRETTE J/AU
E22	12	SURREY A R/AU
E23	122	SURREY ALEXANDER R/AU
E24	1	SURREY ALEXANDER ROBERT/AU
E25	2	SURREY ALLAN/AU

=> E SIRRENBURG C/AU 25

E1	1	SIRRENBURG A/AU
E2	1	SIRRENBURG ANKE/AU
E3	0 -->	SIRRENBURG C/AU
E4	33	SIRRENBURG CHRISTIAN/AU
E5	2	SIRRENBURG S/AU
E6	3	SIRRENBURG W/AU
E7	1	SIRRENBURG WALTER/AU
E8	9	SIRRENBURG WALTHER/AU
E9	75	SIRRENBURG WILHELM/AU
E10	1	SIRRETT D/AU
E11	1	SIRRETTA RAYMOND/AU
E12	2	SIRRETTA RAYMOND J/AU
E13	1	SIRRI A/AU
E14	5	SIRRI ALESSANDRA/AU
E15	1	SIRRI CAM F/AU
E16	1	SIRRI CLOTILDE S/AU
E17	9	SIRRI F/AU
E18	43	SIRRI G/AU
E19	1	SIRRI KES SULEYMAN/AU
E20	1	SIRRI KILIC S/AU
E21	1	SIRRI M/AU
E22	4	SIRRI V/AU
E23	13	SIRRI VALENTINA/AU
E24	4	SIRRIDGE MARJORIE S/AU
E25	1	SIRRINE F A/AU

=> S (E4)

L21 33 ("SIRRENBURG CHRISTIAN"/AU)

=> d his

(FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006

L3 47 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006

L4 83 S L3

L5 77 S L4 AND 1800<=PY<=2001

FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006

L6 0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)  
L7 0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006

L8 STRUCTURE UPLOADED  
L9 50 S L8 SSS SAM  
L10 9805 S L8 SSS FULL

FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006

L11 9054 S L10  
L12 0 S L11 AND L5  
L13 0 S L11 AND L4  
L14 6 S L10 AND CHROMENE  
L15 490 S L10 AND KINASE  
L16 94 S L10 AND TYROSINE KINASE  
E MUJICA F/AU 25  
L17 6 S (E5 OR E6)  
E BUCHHOLZ H/AU 25  
L18 148 S (E3 OR E4 OR E5 OR E6 OR E19 OR E20 OR E21)  
E CAROLA C/AU 25  
L19 37 S (E3 OR E5)  
E RAUTENBERG W/AU 25  
L20 49 S (E3 OR E5 OR E7)  
E SURREBBERG C/AU 25  
E SIRRENNBERG C/AU 25  
L21 33 S (E4)

=> s l16 or l17 or l18 or l19 or l20 or l21  
L22 333 L16 OR L17 OR L18 OR L19 OR L20 OR L21

=> s l22 and kinase  
279466 KINASE  
54347 KINASES  
288351 KINASE  
(KINASE OR KINASES)  
L23 131 L22 AND KINASE

=> s l23 and chrom?  
1576479 CHROM?  
L24 18 L23 AND CHROM?

=> s l24 and l4  
L25 0 L24 AND L4

=> s l23 and l4  
L26 0 L23 AND L4

=> d l24 ibib abs

L24 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:1117612 HCAPLUS Full-text  
DOCUMENT NUMBER: 145:460599  
TITLE: Resorbable implants prepared from a metal base and  
polymer coating with drugs  
INVENTOR(S): Orlowski, Michael  
PATENT ASSIGNEE(S): Germany  
SOURCE: Ger. Offen., 12pp.  
CODEN: GWXXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----  
 DE 102005018356      A1      20061026      DE 2005-102005018356      20050420  
 DE 2005-102005018356      20050420  
 PRIORITY APPLN. INFO.:  
 AB    The invention concerns resorbable implants that are prepared from metals, or metal alloys and coated with biodegradable polymers that include active substances, e.g. anticancer drugs, antiinflammatory agents, antiphlogistics, cytotoxic, antithrombotic agents, corticoids, sex hormones, statins, epothilone, prostacyclins, or angiogenesis inductors. Stents for blood vessels, urinary tract, respiratory tract, bile duct, and gastrointestinal tract can be prepared. Thus a stent was prepared from (weight/weight): zinc 90; magnesium 6; calcium 1; yttrium 2; other metals, salts, nonmetals, carbon, sulfur, oxygen, nitrogen, and(or) hydrogen 1. The stent was dip-coated with a solution of a polyglycol with doxorubicin.  
 REFERENCE COUNT:                      5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 124 ibib abs 2-18

L24 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER:                      2006:909276 HCAPLUS Full-text  
 DOCUMENT NUMBER:                      145:328345  
 TITLE:                                    Application of compound proteasome inhibitor PSI in preparation of medicine for cure of m2 acute myeloid leukemia and chronic myeloid leukemia  
 INVENTOR(S):                            Zhou, Guangbiao; Liu, Dapeng; Hu, Zheng  
 PATENT ASSIGNEE(S):                    Peop. Rep. China  
 SOURCE:                                  Faming Zhuanli Shenqing Gongkai Shuomingshu, 15pp.  
     CODEN: CNXXEV  
 DOCUMENT TYPE:                          Patent  
 LANGUAGE:                                Chinese  
 FAMILY ACC. NUM. COUNT:               1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 1824288	A	20060830	CN 2005-10102194	20051209
PRIORITY APPLN. INFO.:			CN 2005-10102194	20051209
AB	This invention relates to application of compound proteasome inhibitor (PSI) in preparation of medicine for cure of t(8;21) chromosome ectopic M2 acute myeloid leukemia and chronic myeloid leukemia. Title compound PSI is used with cytarabine, daunorubicin, idarubicin, granulocyte colony stimulating factor or granulocyte monocyte colony stimulating factor to cure of M2 acute myeloid leukemia. Title compound PSI is used with cytarabine, hydroxyurea, interferon, or protein tyrosine kinase inhibitor STI-571 to cure of chronic myeloid leukemia.			

L24 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER:                      2006:381897 HCAPLUS Full-text  
 DOCUMENT NUMBER:                      145:486710  
 TITLE:                                    Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance  
 AUTHOR(S):                              Underhill-Day, N.; Pierce, A.; Thompson, S. E.; Xenaki, D.; Whetton, A. D.; Owen-Lynch, P. J.  
 CORPORATE SOURCE:                      Faculty of Life Sciences, Christie Hospital, University of Manchester, Withington, Manchester, UK  
 SOURCE:                                  British Journal of Haematology (2006), 132(6), 774-783  
     CODEN: BJHEAL; ISSN: 0007-1048  
 PUBLISHER:                                Blackwell Publishing Ltd.  
 DOCUMENT TYPE:                          Journal  
 LANGUAGE:                                English  
 AB    Philadelphia chromosome-pos., chronic myeloid leukemia (CML) stem and progenitor cells have a survival and growth advantage compared with their normal counterparts. The mechanisms through which the BCR/ABL protein tyrosine kinase (PTK) induces these effects and the important domains within this protein are not fully defined. The F- and G-actin binding region of the BCR/ABL C-terminus may be important in BCR/ABL-mediated events, and we have investigated this by expressing a C-terminus deletion mutant of the temperature-



sensitive BCR/ABL PTK, in a haemopoietic progenitor cell line, which models the chronic phase of CML. The truncated BCR/ABL PTK displayed similar levels of PTK activity when compared with wild type and activation of second messenger formation (in the form of sn-1,2-diacylglycerol) remains intact. On fibronectin substrata, localization of the protein to the periphery of the cell was, however, dependent on the C-terminus of BCR/ABL PTK. Deletion of the C-terminus reversed both BCR/ABL-mediated apoptotic suppression and drug resistance although the progenitor cells did retain a proliferative advantage at low concns. of growth factor. These results demonstrated that the C-terminal actin-binding domain of BCR/ABL is important for some of BCR/ABL PTK-mediated leukemogenic effects.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:167588 HCAPLUS Full-text

DOCUMENT NUMBER: 144:254148

TITLE: Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy

INVENTOR(S): Munzert, Gerd; Steegmaier, Martin; Baum, Anke

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018182	A1	20060223	WO 2005-EP8623	20050809
WO 2006018182	A8	20060608		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006058311	A1	20060316	US 2005-189540	20050726
PRIORITY APPLN. INFO.:			EP 2004-19361	A 20040814
			EP 2004-19448	A 20040817

OTHER SOURCE(S): MARPAT 144:254148

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to a group of aminopteridinones I, which are useful for the treatment of diseases which involve cell proliferation. In compds. I, R1 and R2 are independently selected from H and (un)substituted C1-6 alkyl, or R1 and R2 together form a 2- to 5-membered alkylene bridge, optionally containing 1 or 2 heteroatoms; R3 is (un)substituted C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-14 aryl, etc.; R4 is H, OH, CN, halo, (un)substituted amino, (un)substituted C1-6 alkyl, C1-5 alkoxy, etc.; L is (un)substituted C2-10 alkylene, (un)substituted C2-10 alkenylene, (un)substituted C6-14 arylene, etc.; R5 is (un)substituted morpholinyl, (un)substituted piperidinyl, (un)substituted piperazinyl, (un)substituted piperazinylcarbonyl, (un)substituted pyrrolidinyl, (un)substituted thiomorpholinyl, etc.; n is 0 or 1; and m is 1 or 2; including tautomers, stereoisomers, salts, solvates, polymorphs, and prodrugs thereof.

The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, at least one other therapeutic agent, optionally with one or more pharmaceutically acceptable excipients, as well as to the use of the compns. for the treatment of diseases which involve cell proliferation, migration or apoptosis of cancer cells, or angiogenesis. Esterification of (R)-2-aminobutyric acid and reductive condensation with cyclopentanone gave cyclopentylamine II, which underwent regioselective substitution of 2,4-dichloro-5-nitropyrimidine and reductive heterocyclization to form pteridinone III. N-Methylation of III followed by substitution with 4-amino-3-methoxybenzoic acid and amidation with 1-methyl-4-aminopiperidine resulted in the formation of aminopterinone IV. A combination of suboptimal doses of irinotecan and compound IV shows an additive/synergistic effect in a human colon carcinoma model and is well tolerated. Meanwhile, compound IV acts at least additively with docetaxel in a human non-small cell lung carcinoma model and not antagonistically with gemcitabine in a human adenocarcinoma model.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1313896 HCAPLUS Full-text  
 DOCUMENT NUMBER: 144:32214  
 TITLE: Treatment methods utilizing albumin-binding proteins as targets  
 INVENTOR(S): Trieu, Vuong; Desai, Neil P.; Soon-Shiong, Patrick  
 PATENT ASSIGNEE(S): American Bioscience, Inc., USA  
 SOURCE: PCT Int. Appl., 32 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117952	A2	20051215	WO 2005-US17174	20050516
WO 2005117952	A3	20060413		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.: US 2004-571622P P 20040514  
 US 2005-654261P P 20050218

AB The invention provides a method for determining the response of a mammalian tumor to a chemotherapeutic agent comprising detecting and quantifying the SPARC protein in a sample isolated from the human. The invention also provides a method for delivering a chemotherapeutic agent to a tumor in a human that expresses SPARC comprising administering a pharmaceutical composition comprising the chemotherapeutic agent coupled to a compound that binds SPARC protein. The invention further provides a composition comprising a chemotherapeutic agent coupled to a compound capable of binding SPARC protein and a pharmaceutically acceptable carrier.

L24 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:824492 HCAPLUS Full-text  
 DOCUMENT NUMBER: 143:222525  
 TITLE: Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function, preparation thereof, and use with other agents  
 INVENTOR(S): Nirschl, Alexandra A.; Hamann, Lawrence G.

PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 25 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005182105	A1	20050818	US 2005-48437	20050201
PRIORITY APPLN. INFO.:			US 2004-541780P	P 20040204
OTHER SOURCE(S):	MARPAT 143:222525			
GI				



AB A method is provided for treating androgen receptor-associated conditions, such as age-related diseases, e.g. sarcopenia, employing a compound I [R1 = CN, H; X = O, S; R2 = (substituted) alkyl, (substituted) cycloalkyl, etc; R3, R4 = H, (substituted) alkyl, etc.; G = (substituted) aryl, (substituted) heteroaryl], or a pharmaceutically acceptable salt or prodrug ester thereof. Preparation of selected I is described. I may be used in combination with other agents.

L24 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:493530 HCAPLUS Full-text  
 DOCUMENT NUMBER: 143:32415  
 TITLE: Soft tissue implants and anti-scarring agents  
 INVENTOR(S): Hunter, William L.; Gravett, David M.; Toleikis, Philip M.; Maiti, Arpita  
 PATENT ASSIGNEE(S): Angiotech International A.-G., Switz.  
 SOURCE: PCT Int. Appl., 2592 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 17  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051444	A2	20050609	WO 2004-US39465	20041122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005148512	A1	20050707	US 2004-986230	20041110
US 2005181977	A1	20050818	US 2004-986231	20041110
AU 2004293075	A1	20050609	AU 2004-293075	20041122
CA 2536192	A1	20050609	CA 2004-2536192	20041122

WO 2005051232	A2	20050609	WO 2004-US39346	20041122
WO 2005051232	A3	20051208		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2006055008	A2	20060526	WO 2004-US39353	20041122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1687041	A2	20060809	EP 2004-812062	20041122
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
CN 1878514	A	20061213	CN 2004-80033341	20041122
US 2005149158	A1	20050707	US 2004-409	20041129
US 2005175662	A1	20050811	US 2004-451	20041129
US 2005175661	A1	20050811	US 2004-999205	20041129
US 2005186243	A1	20050825	US 2004-97	20041129
US 2005186242	A1	20050825	US 2004-999204	20041129
US 2005191331	A1	20050901	US 2004-1419	20041130
US 2005175663	A1	20050811	US 2004-1791	20041202
US 2005181008	A1	20050818	US 2004-1786	20041202
US 2005181011	A1	20050818	US 2004-1792	20041202
US 2005143817	A1	20050630	US 2004-6899	20041207
US 2005177103	A1	20050811	US 2004-6314	20041207
US 2005177225	A1	20050811	US 2004-6895	20041207
US 2005181004	A1	20050818	US 2004-6289	20041207
US 2006147492	A1	20060706	US 2006-343809	20060131
PRIORITY APPLN. INFO.:			US 2003-523908P	P 20031120
			US 2003-524023P	P 20031120
			US 2003-525226P	P 20031124
			US 2003-526541P	P 20031203
			US 2004-578471P	P 20040609
			US 2004-586861P	P 20040709
			US 2004-986230	A 20041110
			US 2004-986231	A 20041110
			US 2003-518785P	P 20031110
			US 2004-582833P	P 20040624
			US 2004-986450	A1 20041110
			WO 2004-US39346	W 20041122
			WO 2004-US39465	W 20041122

AB The invention relates to soft tissue implants for use in cosmetic or reconstructive surgery and to compns. to make the implants resistant to growth by inflammatory scar tissue. Thus, a silicone gel containing paclitaxel was used as a filling in breast implant.

TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis

INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin  
Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;  
Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 101 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1473043	A1	20041103	EP 2003-9587	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004233576	A1	20041111	AU 2004-233576	20040424
CA 2523868	A1	20041111	CA 2004-2523868	20040424
EP 1622619	A2	20060208	EP 2004-729366	20040424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009919	A	20060425	BR 2004-9919	20040424
JP 2006524634	T	20061102	JP 2006-500099	20040424
NO 2005005605	A	20051128	NO 2005-5605	20051128
PRIORITY APPLN. INFO.:			EP 2003-9587	A 20030429
			EP 2004-508	A 20040113
			EP 2004-1171	A 20040121
			WO 2004-EP4363	W 20040424

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preps. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

L24 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:930955 HCAPLUS Full-text

DOCUMENT NUMBER: 141:395558


TITLE: Preparation of heteroaryl chromenones as inhibitors of tyrosine kinases and/or Raf kinases.

INVENTOR(S): Mujica-Fernaund, Teresa; Buchholz, Herwig; Rautenberg, Wilfried; Sirrenberg, Christian

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Eur. Pat. Appl., 38 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1473293	A1	20041103	EP 2004-7549	20040329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
DE 10335782	A1	20041118	DE 2003-10335782	20030805
US 2004220182	A1	20041104	US 2004-833159	20040428
PRIORITY APPLN. INFO.:			DE 2003-10319552	A 20030430
			DE 2003-10335782	A 20030805
OTHER SOURCE(S):			MARPAT 141:395558	
GI				




AB Title compds. [I; R1-R3 = H, OH, OA, PhO, Ar, O2CA, SO2H, SO3A, OSO2A, SO2A, halo, CO2H, CO2A, CONH2, NHSO2A, COA, CHO, SO2NH2; R1R2 = OCH2O, OCH2CH2O; Ar = (substituted) (unsatd.) (aromatic) mono- or binuclear heterocyclyl; A = (fluorinated) alkyl; Ar = (substituted) Ph, naphthyl, biphenyl], were prepared Thus, 1-methylimidazole in THF at -78° was treated with BuLi and then with 6-hydroxy-2-ethoxycarbonylchromen-4-one (preparation given) in THF followed by stirring for 1 h to give 6-hydroxy-2-(1-methyl-1H-imidazol-2-carbonyl)chromen-4-one. The latter inhibited Raf with IC50 >1.0 µM.

L24 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:470326 HCAPLUS Full-text  
 DOCUMENT NUMBER: 141:38618  
 TITLE: Preparation of oxadiazolylchromones as modulators of tyrosine kinase signal transduction.  
 INVENTOR(S): Mujica-Fernaund, Teresa; Buchholz, Herwig; Carola, Christophe; Rautenberg, Wilfried; Sirrenberg, Christian  
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
 SOURCE: Eur. Pat. Appl., 33 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1426372	A1	20040609	EP 2003-26103	20031113
EP 1426372	B1	20060111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
DE 10256182	A1	20040624	DE 2002-10256182	20021202
AT 315564	T	20060215	AT 2003-26103	20031113
ES 2255654	T3	20060701	ES 2003-3026103	20031113

US 2004138464 A1 20040715 US 2003-725346 20031202  
 PRIORITY APPLN. INFO.: DE 2002-10256182 A 20021202  
 OTHER SOURCE(S): MARPAT 141:38618  
 GI



I

AB Title compds. [I; R = A, pyridyl, (substituted) Ph; X = H, OH, PhO, OA, O2CA, SO3H, OSO3H, OSO3A, halo, CO2H, CO2A, CONH2, NHSO2A, COA, CHO, SO2NH2, etc.; A = alkyl, fluoroalkyl; n = 1-4], were prepared. Thus, 2,5-dihydroxyacetophenone and di-Et oxalate were heated 3 h at 80° in EtOH to give 6-hydroxy-2-ethoxycarbonylchromone. This was refluxed with aqueous HCl in HOAc to give 6-hydroxychromon-2-carboxylic acid. The latter in THF at -10° was treated with Et3N and iso-Bu chloroformate; after stirring for 1 h, 4-tert-butylbenzaldoxime in THF was added followed by stirring for 30 min. at room temperature and at reflux for 90 min. to give 6-hydroxy-2-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl] chromone. The latter inhibited Tie2 receptor tyrosine kinase with IC50 >10 µM.

L24 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:466702 HCAPLUS Full-text

DOCUMENT NUMBER: 141:38528

TITLE: Preparation of 2-benzoylchromone derivatives as inhibitors of the tyrosine kinase

INVENTOR(S): Mujica-Fernaund, Teresa; Buchholz, Herwig; Carola, Christophe; Sirrenberg, Christian; Rautenberg, Wilfried

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: Ger. Offen., 22 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10256174	A1	20040609	DE 2002-10256174	20021202
EP 1426378	A1	20040609	EP 2003-25849	20031111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004176440	A1	20040909	US 2003-725349	20031202
PRIORITY APPLN. INFO.:			DE 2002-10256174	A 20021202
OTHER SOURCE(S):	CASREACT 141:38528; MARPAT 141:38528			

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB New compds. I [R = OH, OA, OPh, Ar, OC(:O)A, SO3H, SO3A, OSO3H, OSO3A, OSO2A, SO2A, halogen (F, Cl, I, Br), CO2H, CO2A, CONH2, NHSO2A, COA, CHO, SO2NH2; RR = OCH2O, OCH2CH2O; A = (un)branched C1-10-alkyl, C1-10-fluoroalkyl; Ar = (un)substituted Ph; X =

OH; XX = OCH<sub>2</sub>O, OCH<sub>2</sub>CH<sub>2</sub>O; n = 1 - 4; m = 1 - 5], their pharmaceutically acceptable derivs., solvates and stereoisomers, are inhibitors of the tyrosine kinase and can for the treatment by tumors, to the neuroprotection and for the protection of the stress proteins of the skin is used. The procedure for the preparation of I is characterized by: (a) hydroxyacetophenones II are cyclized with AOC(:O)C(:O)OA (A = C1-6-alkyl) to chromones III; (b) hydrolysis of III to acid IV; (c) chlorination to acid chloride V; (d) Friedel-Crafts acylation of PhRm. Thus, 5-Hydroxy-2-(2,4-dihydroxybenzoyl)chromone (VI) was prepared from 2,6-dihydroxyacetophenone via cyclocondensation with (EtO<sub>2</sub>C)<sub>2</sub>, hydrolysis with aqueous HCl in MeCO<sub>2</sub>H, chlorination with (COCl)<sub>2</sub> in CH<sub>2</sub>Cl<sub>2</sub> containing catalytic DMF, then Friedel-Crafts acylation of resorcinol in THF containing AlCl<sub>3</sub>. Several drug dosage formulations are presented.

L24 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:342284 HCAPLUS Full-text

DOCUMENT NUMBER: 140:350203

TITLE: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

AUTHOR(S): Kantarjian, Hagop; Talpaz, Moshe; O'Brien, Susan; Garcia-Manero, Guillermo; Verstovsek, Srdan; Giles, Francis; Rios, Mary Beth; Shan, Jianqin; Letvak, Laurie; Thomas, Deborah; Faderl, Stefan; Ferrajoli, Alessandra; Cortes, Jorge

CORPORATE SOURCE: Departments of Leukemia and Bioimmunotherapy, M. D. Anderson Cancer Center, The University of Texas, Houston, TX, USA

SOURCE: Blood (2004), 103(8), 2873-2878

CODEN: BLOOAW; ISSN: 0006-4971

PUBLISHER: American Society of Hematology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia (CML). However, most patients treated with 400 mg imatinib daily have variable levels of residual mol. disease. We treated 114 patients with newly diagnosed chronic phase CML with 400 mg imatinib twice daily. Overall, 109 patients (96%) had a major cytogenetic response (Philadelphia chromosome [Ph] < 35%), and 103 (90%) had a complete response (Ph 0%). With a median follow-up of 15 mo, no patient has progressed to accelerated or blastic phase. The estimated 2-yr survival rate was 94%. By quant. polymerase chain reaction (QPCR) studies, 71 (63%) of 112 patients showed BCR-ABL/ABL percentage ratios decrease to less than 0.05%, and 31 (28%) to undetectable levels. Compared with standard-dose imatinib, high-dose imatinib was associated with significantly better complete cytogenetic response (P = .0005), major mol. response (QPCR < 0.05%; P = .00001), and complete mol. response (undetectable BCR-ABL; P = .001). High-dose imatinib was well tolerated but resulted in more frequent myelosuppression; 82% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induced higher rates of complete cytogenetic response and of mol. response in patients with newly diagnosed chronic phase CML.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:100803 HCAPLUS Full-text

DOCUMENT NUMBER: 140:139483

TITLE: Method for enhancing the effectiveness of therapies of hyperproliferative diseases

INVENTOR(S): Chang, Yan; Sasak, Vodek

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 176,235.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004023925	A1	20040205	US 2003-408723	20030407
US 2003013681	A1	20030116	US 2002-176235	20020620
US 6680306	B2	20040120		
CN 1543351	A	20041103	CN 2002-816003	20020621
US 2004043962	A1	20040304	US 2003-657383	20030908
AU 2004229399	A1	20041028	AU 2004-229399	20040407
CA 2521649	A1	20041028	CA 2004-2521649	20040407
WO 2004091634	A1	20041028	WO 2004-US10675	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1617849	A1	20060125	EP 2004-759200	20040407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522163	T	20060928	JP 2006-509773	20040407
PRIORITY APPLN. INFO.:				
			US 2001-299991P	P 20010621
			US 2002-176235	A2 20020620
			US 2003-408723	A 20030407
			US 2003-461006P	P 20030407
			US 2003-474562P	P 20030530
			WO 2004-US10675	W 20040407

AB The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the effectiveness of oncolytic agents. It can also inhibit angiogenesis thereby moderating tumor growth and/or metastasis.

L24 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:41226 HCAPLUS Full-text

DOCUMENT NUMBER: 140:105321

TITLE: Methods and compositions relating to isoleucine boroproline compounds

INVENTOR(S): Adams, Sharlene; Miller, Glenn T.; Jesson, Michael I.; Jones, Barry

PATENT ASSIGNEE(S): Point Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 152 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004658	A2	20040115	WO 2003-US21405	20030709
WO 2004004658	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				

	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
CA 2491466	A1	20040115	CA 2003-2491466 20030709
AU 2003265264	A1	20040123	AU 2003-265264 20030709
US 2004077601	A1	20040422	US 2003-616694 20030709
US 2005084490	A1	20050421	US 2003-616409 20030709
EP 1578434	A2	20050928	EP 2003-763380 20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006507352	T	20060302	JP 2004-562634 20030709
CN 1802090	A	20060712	CN 2003-821282 20030709
CN 1826129	A	20060830	CN 2003-821281 20030709
PRIORITY APPLN. INFO.:			US 2002-394856P P 20020709
			US 2002-414978P P 20021001
			US 2003-466435P P 20030428
			WO 2003-US21405 W 20030709

OTHER SOURCE(S): MARPAT 140:105321

AB A method for treating subjects with, inter alia, abnormal cell proliferation or infectious disease using agents of formula (I, AmNHCH(CH(CH3)CH2CH3)COAlR) (where Am and Al are amino acids and R = organo boronates, organo phosphonates, fluoroalkyl ketones, alphaketos, N-peptidyl-O-(acylhydroxylamines), azapeptides, azetidines, fluoroolefins dipeptide isosteres, peptidyl ( $\alpha$ -aminoalkyl) phosphonate esters, aminoacyl pyrrolidine-2-nitriles and 4-cyanothiazolidides) is claimed. Methods for stimulating an immune response using the compds. of the invention are also claimed. Compns. containing Ile-boroPro compds. are also provided as are kits containing the compns. The invention embraces the use of these compds. alone or in combination with other therapeutic agents.

L24 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:13818 HCAPLUS Full-text

DOCUMENT NUMBER: 138:32998

TITLE: Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia

AUTHOR(S): Liu, Nina Shih; O'Brien, Susan

CORPORATE SOURCE: Department of Leukemia, M.D. Anderson Cancer Center, The University of Texas, Houston, TX, 77030, USA

SOURCE: Leukemia & Lymphoma (2002), 43(12), 2413-2415

CODEN: LELYEA; ISSN: 1042-8194

PUBLISHER: Taylor & Francis Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Imatinib mesylate, a specific inhibitor of the BCR-ABL tyrosine kinase, has been very effective in the treatment of chronic myeloid leukemia (CML) in chronic phase with high rates of hematol. and cytogenetic remissions. Resistance to therapy can develop and transformation to blast crisis may occur, particularly in patients without a cytogenetic response. We report a case of a patient with CML treated in chronic phase who developed blast crisis; withdrawal of imatinib mesylate resulted in spontaneous reversion to chronic phase.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:507951 HCAPLUS Full-text

DOCUMENT NUMBER: 135:87148

TITLE: Metal ion binding site-based method of identifying ligands of biological target molecules for drug discovery

INVENTOR(S): Elling, Christian E.; Gerlach, Lars Ole; Holst Lange, Birgitte; Pedersen, Jan Torleif; Schwartz, Thue W.

PATENT ASSIGNEE(S): 7TM Pharma, Den.

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001050127	A2	20010712	WO 2000-EP13389	20001229
WO 2001050127	A3	20020131		
WO 2001050127	A9	20020912		
WO 2001050127	A8	20040219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395999	A1	20010712	CA 2000-2395999	20001229
US 2002061599	A1	20020523	US 2000-752102	20001229
EP 1242824	A2	20020925	EP 2000-993741	20001229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002054077	A2	20020711	WO 2001-DK867	20011221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:				
		DK 1999-1879	A	19991230
		DK 1999-1880	A	19991230
		US 2000-175401P	P	20000111
		US 2000-175994P	P	20000111
		DK 2000-705	A	20000428
		US 2000-202990P	P	20000509
		WO 2000-EP13389	W	20001229
		DK 2001-536	A	20010330
		US 2001-280237P	P	20010330

OTHER SOURCE(S): MARPAT 135:87148

AB The invention provides a mol. approach for rapidly and selectively identifying small organic mol. ligands, i.e. compds., that are capable of interacting with and binding to specific sites on biol. target mols. The methods of the invention are applicable to any biol. target mol. that has or can be manipulated to have a metal-ion binding site. Biol. target mols. are e.g. proteins, polypeptides, oligopeptides, nucleic acids, carbohydrates, nucleoproteins, glycoproteins, glycolipids, lipoproteins and derivs. thereof. More specifically, the biol. target mols. include membrane receptors, signal transduction proteins, scaffolding proteins, nuclear receptors, steroid receptors, intracellular receptors, transcription factors, enzymes, allosteric enzyme regulatory proteins, growth factors, hormones, neuropeptides and Igs. A very interesting group of biol. target mols. are membrane proteins such as, e.g., transmembrane protein (e.g. 7 TMs). The methods described herein make it possible to construct and screen libraries of compds. specifically directed against predetd. epitopes on the biol. target mols. The compds. are initially constructed to be bifunctional, i.e. having both a metal-ion binding moiety, which conveys them with the ability to bind to either a natural or an artificially constructed metal-ion binding site as well as a variable moiety, which is varied chemical to probe for interactions with specific parts of the biol. target mol. located spatially adjacent to the metal-ion binding site. Compds. may subsequently be further modified to bind to the unmodified biol. target mol. without help of the bridging metal-ion. The methods according to the invention may be performed easily and quickly and lead to unambiguous results. The compds. identified by the methods may themselves be

employed for various applications or may be further derivatized or modified to provide novel compds. The methodol. of the invention is useful in drug discovery.

L24 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:394904 HCAPLUS Full-text

DOCUMENT NUMBER: 135:174865

TITLE: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

AUTHOR(S): Kano, Yasuhiko; Akutsu, Miyuki; Tsunoda, Saburo; Mano, Hiroyuki; Sato, Yuko; Honma, Yoshio; Furukawa, Yusuke

CORPORATE SOURCE: Division of Hematology and Medical Oncology, Tochigi Cancer Center, Tochigi, 320-0834, Japan

SOURCE: Blood (2001), 97(7), 1999-2007

CODEN: BLOOAW; ISSN: 0006-4971

PUBLISHER: American Society of Hematology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The BCR/ABL tyrosine kinase has been implicated in the pathogenesis of chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL). STI571 is a novel anticancer agent that selectively inhibits the BCR/ABL tyrosine kinase. The cytotoxic effects of STI571 were studied in combination with antileukemic agents against Ph+ leukemia cell lines, KU812, K-562, TCC-S, and TCC-Y. The cells were exposed to STI571 and to other agents simultaneously for 5 or 7 days. Cell growth inhibition was determined by MTT assay. The cytotoxic effects in combinations at the inhibitory concentration of 80% level were evaluated by the isobologram. STI571 produced synergistic effects with recombinant and natural  $\alpha$ -interferons in 2 of 3 and 3 of 3 cell lines, resp. STI571 produced additive effects with hydroxyurea, cytarabine, homoharringtonine, doxorubicin, and etoposide in all 4 cell lines. STI571 with 4-hydroperoxy-cyclophosphamide, methotrexate, or vincristine produced additive, antagonistic, and synergistic effects in 3 of 4 cell lines, resp. These findings suggest that the simultaneous administration of STI571 with other agents except methotrexate would be advantageous for cytotoxic effects against Ph+ leukemias. Among them, the simultaneous administration of STI571 and  $\alpha$ -interferons or vincristine would be highly effective against Ph+ leukemias and these combinations would be worthy of clin. trials. In contrast, the simultaneous administration of STI571 with methotrexate would have little therapeutic efficacy. Although there are gaps between in vitro studies and clin. trials, the present findings provide useful information for the establishment of clin. protocols involving STI571.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:99301 HCAPLUS Full-text

DOCUMENT NUMBER: 116:99301

TITLE: Maleic anhydride copolymers as antidotes for the cytotoxicity of neoplasm inhibitors

INVENTOR(S): Bach, Ardalan; Shanahan, William R., Jr.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: Eur. Pat. Appl., 27 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 393575	A1	19901024	EP 1990-107246	19900417
EP 393575	B1	19940316		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2014732	A1	19901017	CA 1990-2014732	19900417
JP 02292227	A	19901203	JP 1990-101530	19900417
AT 102838	T	19940415	AT 1990-107246	19900417


ES 2062155  
PRIORITY APPLN. INFO.:

T3 19941216

ES 1990-107246  
US 1989-339503  
EP 1990-107246

19900417  
A 19890417  
A 19900417

OTHER SOURCE(S): MARPAT 116:99301  
GI



AB Half-amide:half-imide copolymers comprising ethylene and maleic anhydride moieties (structure given), specifically carbetimer (I; a/b = 1:2-5), decrease the cytotoxic side effects of neoplasm inhibitors. Mice treated i.v. with 21 mg adriamycin/kg died within 5 days. When 1700 mg I/kg was administered concomitantly, no lethality was shown for >30 days.

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

89.85

437.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-14.25

-14.25

FILE 'STNGUIDE' ENTERED AT 18:12:57 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 19, 2006 (20061219/UP).

=>

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.64

440.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-14.25

FILE 'STNGUIDE' ENTERED AT 18:39:05 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	1.26	441.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-14.25

FILE 'HCAPLUS' ENTERED AT 18:51:46 ON 19 DEC 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26  
 FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s flavanoid?  
 L27 1300 FLAVANOID?

=> s kinase  
 279466 KINASE  
 54347 KINASES  
 L28 288351 KINASE  
 (KINASE OR KINASES)

=> s 127 and 128  
 L29 14 L27 AND L28

=> d 129 ibib

L29 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2006:1220504 HCAPLUS Full-text  
 TITLE: Apigenin inhibition of involucrin gene expression is associated with a specific reduction in phosphorylation of protein kinase C $\delta$  Tyr311  
 AUTHOR(S): Balasubramanian, Sivaprakasam; Zhu, Ling; Eckert, Richard L.  
 CORPORATE SOURCE: Department of Physiology and Biophysics, Case Western Reserve University School of Medicine, Cleveland, OH, 44106-4970, USA  
 SOURCE: Journal of Biological Chemistry (2006), 281(47), 36162-36172  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PUBLISHER: American Society for Biochemistry and Molecular Biology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 85 THERE ARE 85 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 129 ibib 2

L29 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:584435 HCAPLUS Full-text  
DOCUMENT NUMBER: 145:137165  
TITLE: Prostate cancer chemoprevention by Silibinin: bench to bedside  
AUTHOR(S): Singh, Rana P.; Agarwal, Rajesh  
CORPORATE SOURCE: Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, CO, USA  
SOURCE: Molecular Carcinogenesis (2006), 45(6), 436-442  
CODEN: MOCAE8; ISSN: 0899-1987  
PUBLISHER: Wiley-Liss, Inc.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s tyrosine kinase  
155428 TYROSINE  
2627 TYROSINES  
155960 TYROSINE  
(TYROSINE OR TYROSINES)  
279466 KINASE  
54347 KINASES  
288351 KINASE  
(KINASE OR KINASES)  
L30 42816 TYROSINE KINASE  
(TYROSINE(W) KINASE)

=> s l30 and l29  
L31 3 L30 AND L29

=> d l31 ibib abs

L31 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:584435 HCAPLUS Full-text  
DOCUMENT NUMBER: 145:137165  
TITLE: Prostate cancer chemoprevention by Silibinin: bench to bedside  
AUTHOR(S): Singh, Rana P.; Agarwal, Rajesh  
CORPORATE SOURCE: Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, CO, USA  
SOURCE: Molecular Carcinogenesis (2006), 45(6), 436-442  
CODEN: MOCAE8; ISSN: 0899-1987  
PUBLISHER: Wiley-Liss, Inc.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Prostate cancer (PCA) is the most invasive malignancy and second leading cause of cancer deaths in American males. One approach to reduce PCA incidence, growth, and metastasis is prevention and intervention targeted towards mitogenic and survival signaling and cell-cycle regulation. This approach is based on the rationale that overexpression of receptor tyrosine kinases (RTKs) and(or) non-receptor tyrosine kinases leads to persistent autocrine stimulation of malignant cells for deregulated cell-cycle progression and uncontrolled growth. PCA progression has also been associated with transition from a paracrine to an autocrine relation between receptors and growth ligands as this malignancy progresses to an advanced androgen-independent aggressive stage. Together, these studies suggest that targeting RTK-mediated signaling pathways along with cell-cycle regulators could be a practical and translational approach for PCA prevention and intervention. Here, the authors provide evidence that a naturally occurring nontoxic flavanoid, Silibinin, targets the epidermal growth factor receptor (EGFR), insulin-like

growth factor-1 receptor (IGF-1R), and NF- $\kappa$ B (nuclear factor-kappa B) pathways in PCA. Furthermore, it modulates cell-cycle regulators, including cyclin-dependent kinases (CDKs), Cip/Kip, and cyclins for its anticancer efficacy against PCA. Silibinin inhibits the growth of PCA cells from human, mouse, and rat origins, and also suppresses human prostate tumor xenograft growth in nude mice. Silibinin also inhibits PCA growth in the transgenic adenocarcinoma of mouse prostate (TRAMP) mouse model. Now, Silibinin has been entered into phase I/II clin. trials in human PCA patients where preliminary observations were suggestive of its further study in a larger base of the patient population.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l31 ibib abs 2-6

L31 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:45494 HCAPLUS Full-text

DOCUMENT NUMBER: 128:119463

TITLE: The plans of the genus *Phyllanthus* as a potential source of new drugs

AUTHOR(S): Calixto, Joao B.; Santos, Adair R. S.; Paulino, Niraldo; Cechinel Filho, Valdir; Yunes, Rosendo A.

CORPORATE SOURCE: Departamento de Farmacologia, Universidade Federal de Santa Catarina, Florianopolis, 88015-420, Brazil

SOURCE: Ciencia e Cultura (Sao Paulo) (1997), 49(5/6), 422-432  
CODEN: CCUPAD; ISSN: 0009-6725

PUBLISHER: Sociedade Brasileira para o Progresso da Ciencia

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review with 157 refs. The plants of the genus *Phyllanthus* (Euphorbiaceae) comprise about 550 to 750 species which are widely distributed in most tropical and subtropical countries. About 200 species are believed to occur in the Americas, mainly in the Caribbean and Brazil. The plants of the genus *Phyllanthus* have long been used in folk medicine to treat, among others, kidney and urinary bladder disorders, intestinal infections, diabetes and hepatitis B. In recent years, substantial progress in chemical and pharmacol. studies, and a few clin. studies of some *Phyllanthus* species, were made. This review discusses the current knowledge gained by the in vitro and in vivo pharmacol. and biochem. studies performed with the exts. and the main active constituents isolated from different species of plants of the genus *Phyllanthus*. Data available in the literature strongly support the idea that th extract and some constituents isolated from these plants, including flavanoids, tannins, alkaloids, coumarins, lignans and terpenes, account for their reported antinociceptive, anti-inflammatory, antiviral, antispasmodic and antiallergic properties. In addition, some of these compds. interact with most key enzymes, such as aldose reductase, angiotensin converting enzyme, mitochondrial ATPase, both cyclo- and lipooxygenases, phospholipase A2, tyrosine kinase, reverse transcriptase, and phosphodiesterases. The complex mechanism of action of such compds. could explain, at least in part, the wide therapeutic use of the plants of the genus *Phyllanthus* in folk medicine. Thus, the plants of the genus *Phyllanthus* present potential therapeutic interest as a source of new drugs.

REFERENCE COUNT: 157 THERE ARE 157 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1990:32520 HCAPLUS Full-text

DOCUMENT NUMBER: 112:32520

TITLE: Inhibition of protein-tyrosine kinase activity by flavanoids and related compounds

AUTHOR(S): Geahlen, Robert L.; Koonchanok, Nuphavan M.; McLaughlin, Jerry L.; Pratt, Dan E.

CORPORATE SOURCE: Sch. Pharm. Pharm. Sci., Purdue Univ., West Lafayette, IN, 47907, USA

SOURCE: Journal of Natural Products (1989), 52(5), 982-6  
CODEN: JNPRDF; ISSN: 0163-3864

DOCUMENT TYPE: Journal



LANGUAGE: English

AB A series of 22 flavanoids and related compds. were tested for their ability to inhibit the activity of a protein-tyrosine kinase purified from bovine thymocytes (p40). Flavones or flavanols with hydroxyl groups at C-5 and C-7 or with 3 hydroxyl groups on the Ph ring were potent inhibitors of p40. The replacement of hydroxyl groups with methoxyl groups led to a substantial loss of inhibitory activity. The presence of methoxyl or rhamnosyl substituents at C-3 also abolished inhibitory activity. Kinetic analyses indicated that the flavone apigenin was a competitive inhibitor of p40 with respect to ATP. Flavanones and isoflavones were relatively inactive as protein-tyrosine kinase inhibitors. The isoflavone genistein, which has been reported as a potent inhibitor of both pp60 and the epidermal growth factor receptor, was not an inhibitor of p40.

=> f stng

L32 2 STNG

=> file stng

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

20.62	462.28
-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-2.25	-16.50
-------	--------

FILE 'STNGUIDE' ENTERED AT 18:53:55 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> d his

(FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006

L3 47 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006

L4 83 S L3

L5 77 S L4 AND 1800<=PY<=2001

FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006

L6 0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)

L7 0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006

L8 STRUCTURE UPLOADED

L9 50 S L8 SSS SAM

L10 9805 S L8 SSS FULL

FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006

L11 9054 S L10  
L12 0 S L11 AND L5  
L13 0 S L11 AND L4  
L14 6 S L10 AND CHROMENE  
L15 490 S L10 AND KINASE  
L16 94 S L10 AND TYROSINE KINASE  
E MUJICA F/AU 25  
L17 6 S (E5 OR E6)  
E BUCHHOLZ H/AU 25  
L18 148 S (E3 OR E4 OR E5 OR E6 OR E19 OR E20 OR E21)  
E CAROLA C/AU 25  
L19 37 S (E3 OR E5)  
E RAUTENBERG W/AU 25  
L20 49 S (E3 OR E5 OR E7)  
E SURREBBERG C/AU 25  
E SIRRENBERG C/AU 25  
L21 33 S (E4)  
L22 333 S L16 OR L17 OR L18 OR L19 OR L20 OR L21  
L23 131 S L22 AND KINASE  
L24 18 S L23 AND CHROM?  
L25 0 S L24 AND L4  
L26 0 S L23 AND L4

FILE 'STNGUIDE' ENTERED AT 18:12:57 ON 19 DEC 2006

FILE 'STNGUIDE' ENTERED AT 18:39:05 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 18:51:46 ON 19 DEC 2006

L27 1300 S FLAVANOID?  
L28 288351 S KINASE  
L29 14 S L27 AND L28  
L30 42816 S TYROSINE KINASE  
L31 3 S L30 AND L29  
L32 2 F STNG

FILE 'STNGUIDE' ENTERED AT 18:53:55 ON 19 DEC 2006

=> fil hcaplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.12	462.40

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-16.50

CA SUBSCRIBER PRICE

FILE 'HCAPLUS' ENTERED AT 18:55:11 ON 19 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26  
FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> fil stng

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.18	477.58
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-16.50

FILE 'STNGUIDE' ENTERED AT 18:58:47 ON 19 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	477.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-16.50

FILE 'HCAPLUS' ENTERED AT 18:59:14 ON 19 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26  
FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 17:31:36 ON 19 DEC 2006)

FILE 'REGISTRY' ENTERED AT 17:31:40 ON 19 DEC 2006

L1 STRUCTURE UPLOADED  
L2 0 S L1 SSS SAM

FILE 'STNGUIDE' ENTERED AT 17:32:25 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 17:33:21 ON 19 DEC 2006

```

L3          47 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 17:33:58 ON 19 DEC 2006
L4          83 S L3
L5          77 S L4 AND 1800<=PY<=2001

FILE 'STNGUIDE' ENTERED AT 17:34:57 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 17:44:11 ON 19 DEC 2006
L6          0 S L5 AND ( 4H-1-BENZOPYRAN-2-CARBONYL CHLORIDE METHYL OXO)
L7          0 S L5 AND (CARBONYL CHLORIDE METHYL OXO)

FILE 'STNGUIDE' ENTERED AT 17:45:21 ON 19 DEC 2006

FILE 'REGISTRY' ENTERED AT 18:03:05 ON 19 DEC 2006
L8          STRUCTURE UPLOADED
L9          50 S L8 SSS SAM
L10         9805 S L8 SSS FULL

FILE 'HCAPLUS' ENTERED AT 18:04:30 ON 19 DEC 2006
L11         9054 S L10
L12         0 S L11 AND L5
L13         0 S L11 AND L4
L14         6 S L10 AND CHROMENE
L15         490 S L10 AND KINASE
L16         94 S L10 AND TYROSINE KINASE
            E MUJICA F/AU 25
L17         6 S (E5 OR E6)
            E BUCHHOLZ H/AU 25
L18         148 S (E3 OR E4 OR E5 OR E6 OR E19 OR E20 OR E21)
            E CAROLA C/AU 25
L19         37 S (E3 OR E5)
            E RAUTENBERG W/AU 25
L20         49 S (E3 OR E5 OR E7)
            E SURREBBERG C/AU 25
            E SIRRENNBERG C/AU 25
L21         33 S (E4)
L22         333 S L16 OR L17 OR L18 OR L19 OR L20 OR L21
L23         131 S L22 AND KINASE
L24         18 S L23 AND CHROM?
L25         0 S L24 AND L4
L26         0 S L23 AND L4

FILE 'STNGUIDE' ENTERED AT 18:12:57 ON 19 DEC 2006

FILE 'STNGUIDE' ENTERED AT 18:39:05 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 18:51:46 ON 19 DEC 2006
L27         1300 S FLAVANOID?
L28         288351 S KINASE
L29         14 S L27 AND L28
L30         42816 S TYROSINE KINASE
L31         3 S L30 AND L29
L32         2 F STNG

FILE 'STNGUIDE' ENTERED AT 18:53:55 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 18:55:11 ON 19 DEC 2006

FILE 'STNGUIDE' ENTERED AT 18:58:47 ON 19 DEC 2006

FILE 'HCAPLUS' ENTERED AT 18:59:14 ON 19 DEC 2006

=> s oxal?
L33         122622 OXAL?

```

=> s 133 and 116  
L34 20 L33 AND L16

=> s 133 and 117  
L35 3 L33 AND L17


=> s 133 and 15  
L36 11 L33 AND L5

=> d 136 ibib abs hitstr


L36 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2001:300703 HCAPLUS Full-text  
DOCUMENT NUMBER: 134:311230  
TITLE: Preparation of benzopyran derivatives as adrenergic  
antagonists  
INVENTOR(S): Leonardi, Amedeo; Motta, Gianni; Riva, Carlo; Sironi,  
Giorgio  
PATENT ASSIGNEE(S): Recordati Industria Chimica E Farmaceutica Spa, Italy;  
Recordati S. A., Chemical and Pharmaceutical Company  
SOURCE: PCT Int. Appl., 61 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001029022	A1	20010426	WO 2000-EP10143	20001016 <--
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
IT 99MI2174	A1	20010418	IT 1999-MI2174	19991018 <--
IT 1314192	B1	20021206		
EP 1222183	A1	20020717	EP 2000-975868	20001016
EP 1222183	B1	20030423		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL	
JP 2003512366	T	20030402	JP 2001-531822	20001016
AT 238291	T	20030515	AT 2000-975868	20001016
PT 1222183	T	20030829	PT 2000-975868	20001016
ES 2197123	T3	20040101	ES 2000-975868	20001016
US 6403594	B1	20020611	US 2000-691770	20001018
PRIORITY APPLN. INFO.:			IT 1999-MI2174	A 19991018
			US 2000-218721P	P 20000717
			WO 2000-EP10143	W 20001016

OTHER SOURCE(S): MARPAT 134:311230  
GI



- AB N-(4-phenylpiperazin-1-ylalkyl)-2-oxobenzopyran-8-carboxamide derivs. (I; R = Ph, alkoxy carbonyl, alkyl carbonyl, CONH<sub>2</sub>, CONH(alkyl), CON(alkyl)<sub>2</sub>, cyano, or alkoxy carbonylamino; R<sub>2</sub> = alkyl, alkoxy, polyfluoroalkoxy, OH, or CF<sub>3</sub>SO<sub>2</sub>O; each of R<sub>4</sub> and R<sub>5</sub> independently = H, halogen, polyfluoroalkyl, polyfluoroalkoxy, cyano or CONH<sub>2</sub>; n is 0, 1 or 2; but if R = Ph and both of R<sub>4</sub> and R<sub>5</sub> = H or halogen atoms, then R<sub>2</sub> = polyfluoroalkoxy or CF<sub>3</sub>SO<sub>2</sub>O) and their N-oxides and pharmaceutically acceptable salts are prepared. These compds. are endowed with adrenergic antagonist activity and, in particular, with high selectivity for the α<sub>1</sub>-adrenergic receptor as compared to the 5-HT<sub>1A</sub> receptor. This activity profile suggests the use of these benzopyran derivs. for preventing contractions (including noradrenaline-related contractions) of the urethra and lower urinary tract in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), without side-effects associated with hypotensive activity. They are also useful for treating high intraocular pressure, cardiac arrhythmia, or sexual dysfunction, inhibiting the synthesis of cholesterol, and reducing sympathetically-mediated pain. Thus, 1-(3-aminopropyl)-4-(5-chloro-2-methoxyphenyl)piperazine trihydrochloride was condensed with 8-Carboxy-2-((1,1-dimethylethoxycarbonyl)amino)-3-methyl-4H-1-benzopyran using di-Et cyanophosphate in the presence of Et<sub>3</sub>N in DMF at 0-25° for 4 h to give 2-((1,1-dimethylethoxycarbonyl)amino)-8-[[3-[4-(5-chloro-2-methoxyphenyl)-1-piperazinyl]propyl]carbonyl]-3-methyl-4-oxo-4H-1-benzopyran monohydrate which in vitro showed affinity to cloned α<sub>1a</sub>, α<sub>1b</sub>, α<sub>1d</sub>, and 5-HT<sub>1A</sub> receptor with K<sub>i</sub> of 0.20, 0.32, 0.45, and 81.87 nM, resp.
- IT 335086-82-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of benzopyran derivs. as α<sub>1</sub>-adrenergic antagonists for treating diseases associated with overactivity of said receptor)
- RN 335086-82-3 HCAPLUS
- CN 4H-1-Benzopyran-2-carbonyl chloride, 3-methyl-4-oxo-8-(1-propenyl)- (9CI)  
 (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l36 ibib abs hitstr 2-16

L36 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1987:156223 HCAPLUS Full-text  
 DOCUMENT NUMBER: 106:156223

TITLE: Benzopyrones. Part 23. Cyclization of o-amino carboxamides and related compounds

AUTHOR(S): Bevan, Peter S.; Ellis, Gwynn P.; Hudson, Henrietta V.; Romney-Alexander, Trevor M.; Williams, J. Michael

CORPORATE SOURCE: Inst. Sci. Technol., Univ. Wales, Cardiff, CF1 3XF, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1986), (9), 1643-9


CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:156223


GI




I




II



III




IV




V

- AB Cyclization of chromenecarboxamide I ( $R = H$ ,  $R_1 = Br$ ,  $R_2 = NH_2$ ,  $R_3 = CONH_2$ ) with  $EtO_2CCO_2Et-NaOEt$  gave the benzopyranopyrimidinedione II. I ( $R = H$ ,  $R_1 = CO_2Et$ ,  $R_2 = CONH_2$ ,  $R_3 = NH_2$ ) in a similar reaction gave benzopyranopyrimidine III but when I ( $R$ ,  $R_1 = H$ ,  $R_2 = CONH_2$ ,  $R_3 = NH_2$ ) was subjected to the same reaction, benzopyranodiazepine IV was obtained in high yield. This structure, which contains the hitherto unknown 1,4-diazepine-2,3,5-trione ring, is supported by spectroscopic and chemical evidence. The presence of a 3-amino and a 2-carbonyl group in a chromone has an unexpected shielding effect on the chemical shift of C-8. The course of the cyclization was studied. Attempts to cyclize I ( $R$ ,  $R_1 = H$ ,  $R_2 = CONH_2$ ,  $R_3 = CH_2NH_2$ ) failed but a new ring system V was obtained when I ( $R$ ,  $R_1 = H$ ,  $R_2 = CO_2Et$ ,  $R_3 = Br$ ) reacted with 2-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>.
- IT 107691-27-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and esterification of)
- RN 107691-27-0 HCAPLUS
- CN 4H-1-Benzopyran-2-carbonyl chloride, 3-bromo-4-oxo- (9CI) (CA INDEX NAME)




L36 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1987:119624 HCAPLUS Full-text  
 DOCUMENT NUMBER: 106:119624  
 TITLE: Synthesis of  $^{14}\text{C}$ -bucromarone succinate and hydrochloride  
 AUTHOR(S): Nicolas, Colette; Verny, Michel; Maurizis, Jean Claude; Payard, Marc; Faurie, Michel  
 CORPORATE SOURCE: INSERM U 71, Clermont-Ferrand, 63005, Fr.  
 SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals (1986), 23(8), 837-44  
 CODEN: JLCRD4; ISSN: 0362-4803  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 106:119624  
 GI



AB  $^{14}\text{C}$ -bucromarone I was prepared from  $\text{HO}^{14}\text{C}^{14}\text{CO}_2\text{H}$ . The labeling took place at the first step of the synthesis, and  $^{14}\text{C}$ -bucromarone succinate, with a specific activity of 7.45 mCi/mmol, and  $^{14}\text{C}$ -bucromarone hydrochloride, with a specific activity of 7.5 mCi/mmol, were obtained.





IT 107139-53-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and Friedel-Crafts reaction of, with dimethylphenol)

RN 107139-53-7 HCAPLUS  
 CN 4H-1-Benzopyran-2- $^{14}\text{C}$ -2-carbonyl- $^{14}\text{C}$  chloride, 4-oxo- (9CI) (CA INDEX NAME)




L36 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1981:103331 HCAPLUS Full-text  
 DOCUMENT NUMBER: 94:103331  
 TITLE: Heterocyclic nitrogen derivatives  
 INVENTOR(S): Cox, David; Cairns, Hugh; Chadwick, Nigel; Suschitzky, John Louis  
 PATENT ASSIGNEE(S): Fisons Ltd., UK  
 SOURCE: Ger. Offen., 122 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent





- AB Antiallergic (no data) pyrano[3,2-d]quinolinedicarboxylic acids and related compds. were prepared. Thus, the aniline I was treated with MeO<sub>2</sub>CC.tplbond.CCO<sub>2</sub>Me and the resulting fumarate cyclized to give II which was chlorinated and treated with MeNH<sub>2</sub> to give the amide III. III was hydrolyzed and esterified to the Et ester which was treated with di-Et oxalate to give the ester IV (R = Et). The latter was saponified to IV (R = Na).
- IT 75453-71-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and hydrolysis of)
- RN 75453-71-3 HCAPLUS
- CN 4H-Pyrano[3,2-g]quinoline-2,8-dicarbonyl dichloride, 6-chloro-4-oxo-10-propyl- (9CI) (CA INDEX NAME)



L36 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1981:30488 HCAPLUS Full-text

DOCUMENT NUMBER: 94:30488

TITLE: Benzopyrones. Part 16. Synthesis of  
 3-alkyl-4-oxochromen-2-carboxylic acids,  
 3-alkyl-2-methylchromen-4-ones, and related compounds

AUTHOR(S): Buggy, Thomas; Ellis, Gwynn P.

CORPORATE SOURCE: Dep. Chem., Univ. Wales Inst. Sci. Technol., Cardiff,  
 CF1 3NU, UK

SOURCE: Journal of Chemical Research, Synopses (1980  
 ), (9), 317  
 CODEN: JRPSDC; ISSN: 0308-2342

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 94:30488

GI

LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2943658	A1	19800514	DE 1979-2943658	19791029 <--
DE 2943658	C2	19910801		
GB 2035312	A	19800618	GB 1979-36401	19791019 <--
GB 2035312	B	19821020		
FR 2440371	A1	19800530	FR 1979-26530	19791025 <--
FR 2440371	B1	19830128		
CA 1142520	A1	19830308	CA 1979-338555	19791026 <--
FI 7903369	A	19800501	FI 1979-3369	19791029 <--
FI 67702	B	19850131		
FI 67702	C	19850510		
NL 7907916	A	19800502	NL 1979-7916	19791029 <--
NO 7903469	A	19800502	NO 1979-3469	19791029 <--
NO 154522	B	19860630		
NO 154522	C	19861008		
AU 7952287	A	19800508	AU 1979-52287	19791029 <--
AU 528648	B2	19830505		
BR 7907006	A	19800715	BR 1979-7006	19791029 <--
ZA 7905789	A	19801126	ZA 1979-5789	19791029 <--
PL 130691	B1	19840831	PL 1979-219304	19791029 <--
CS 231166	B2	19841015	CS 1979-7359	19791029 <--
IL 58579	A	19851231	IL 1979-58579	19791029 <--
BE 879737	A1	19800430	BE 1979-197902	19791030 <--
DK 7904586	A	19800501	DK 1979-4586	19791030 <--
SE 7908995	A	19800501	SE 1979-8995	19791030 <--
SE 451071	B	19870831		
SE 451071	C	19871210		
JP 55064572	A	19800515	JP 1979-139422	19791030 <--
JP 03018639	B	19910313		
ES 485517	A1	19800901	ES 1979-485517	19791030 <--
DD 146954	A5	19810311	DD 1979-216552	19791030 <--
SU 1014476	A3	19830423	SU 1979-2838414	19791030 <--
HU 26391	A2	19830928	HU 1979-FI718	19791030 <--
HU 183087	B	19840428		
CH 643264	A5	19840530	CH 1979-9715	19791030 <--
AT 7907014	A	19850715	AT 1979-7014	19791030 <--
AT 379811	B	19860310		
US 4419352	A	19831206	US 1981-236329	19810220 <--
FI 8103127	A	19811008	FI 1981-3127	19811008 <--
NO 8502258	A	19800502	NO 1985-2258	19850604 <--
NO 156692	B	19870727		
NO 156692	C	19871104		
PRIORITY APPLN. INFO.:			GB 1978-42679	A 19781031
			GB 1979-20760	A 19790614
			US 1979-82994	A1 19791009
			GB 1979-36401	A 19791019
			FI 1979-3369	A 19791029

GI




AB Novel 3-alkylchromen-4-ones were prepared by 2 previously reported methods. Thus, using the method of W. D. Ollis et al. (1953), the decanophenone I (R = H, R1 = Me) was reacted to give 58% oxochromenecarboxylic acid which was converted to its n-hexyl ester II [R = H, R1 = Me, R2 = CO2(CH2)5Me]. By the Kostanecki-Robinson reaction, the decanophenone I (R = OH, R1 = H) was refluxed with Ac2O/NaOAc for 56 h to give the chromenone II (R = OAc, R1 = H, R2 = Me). The new type of chromenone, III, was prepared using this method.

IT 76115-99-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and esterification of)

RN 76115-99-6 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 6-methyl-3-octyl-4-oxo- (9CI) (CA INDEX NAME)



L36 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1977:72660 HCAPLUS Full-text

DOCUMENT NUMBER: 86:72660

TITLE: Chromone and thiachromone carboxyamido tetrazoles

INVENTOR(S): Augstein, Joachim; Cairns, Hugh; Rogers, Norman Harold

PATENT ASSIGNEE(S): Fisons Ltd., UK

SOURCE: Brit., 21 pp. Division of Brit. 1,447,479.  
 CODEN: BRXXAA



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1447480	A	19760825	GB 1973-39041	19731129 <--
DE 2361490	A1	19740627	DE 1973-2361490	19731210 <--
FR 2210405	A1	19740712	FR 1973-44703	19731214 <--
JP 49094675	A	19740909	JP 1973-138874	19731214 <--
PRIORITY APPLN. INFO.:			GB 1972-57901	A 19721215
			GB 1973-39041	A 19730817
			GB 1973-39042	A 19730817
			GB 1973-39044	A 19730817
			GB 1973-39045	A 19730817



```

RN      42047-74-5   HCAPLUS
CN      4H-1-Benzopyran-2-carbonyl chloride, 5-(3-methylbutoxy)-4-oxo-8-(2-
        propenyl)- (9CI)  (CA INDEX NAME)


```




IT 53542-83-9P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and condensation with aminotetrazole)

RN 53542-83-9 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 5,5'-[[2-(formyloxy)-1,3-propanediyl]bis(oxy)]bis[4-oxo- (9CI) (CA INDEX NAME)



L36 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1976:413871 HCAPLUS Full-text  
 DOCUMENT NUMBER: 85:13871  
 TITLE: Study of the pharmacodynamic properties of heptaminol  
 chromonecarboxamide in the central nervous system  
 AUTHOR(S): Foussard-Blanpin, Odette; Moreau, C.; Niviere, P.  
 CORPORATE SOURCE: Lab. Pharmacodyn. Chim. Ther., U.E.R. Sci. Pharm.,  
 Tours, Fr.  
 SOURCE: Therapie (1975), 30(6), 877-86  
 CODEN: THERAP; ISSN: 0040-5957  
 DOCUMENT TYPE: Journal  
 LANGUAGE: French  
 GI




AB While heptaminol-HCl [543-15-7] (120 or 240 mg/kg, orally) facilitated exploratory behavior, slightly increased rectal temperature, and increased excitability in mice, heptaminol-2-chromonecarboxamide (I) [58243-46-2] (250 or 500 mg/kg, orally) had a depressive effect on these parameters. I attenuated the behavioral response to and toxicity of amphetamine, prolonged chloral hydrate- or pentobarbital-induced sleep, enhanced reserpine-induced palpebral ptosis and increased the hypothermic and cataleptic response to chlorpromazine. Heptaminol-HCl increased amphetamine toxicity and behavioral excitation and decreased the response to neuroleptics and hypnotics. The preparation of I is described.

IT 5112-47-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, with heptaminol)

RN 5112-47-0 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1974:520633 HCAPLUS Full-text

DOCUMENT NUMBER: 81:120633

TITLE: 4-Oxo-4H-1-benzopyran and 4-oxo-4H-1-thiobenzopyron derivatives

INVENTOR(S): Augstein, Joachim; Cairns, Hugh; Rogers, Norman Harold

PATENT ASSIGNEE(S): Fisons Ltd.

SOURCE: Ger. Offen., 45 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2361490	A1	19740627	DE 1973-2361490	19731210 <--
GB 1447479	A	19760825	GB 1972-57901	19731129 <--
GB 1447480	A	19760825	GB 1973-39041	19731129 <--
PRIORITY APPLN. INFO.:			GB 1972-57901	A 19721215
			GB 1973-39041	A 19730817
			GB 1973-39042	A 19730817
			GB 1973-39044	A 19730817
			GB 1973-39045	A 19730817

GI For diagram(s), see printed CA Issue.

AB Immunosuppressant (no data) benzopyrancarboxamidotetrazoles I (R = Me, CH<sub>2</sub>-Ph, R<sub>1</sub> = R<sub>2</sub> = H; R = H, R<sub>1</sub> = OCH<sub>2</sub>CH<sub>2</sub>CHMe<sub>2</sub>, R<sub>2</sub> = allyl; R = H, R<sub>1</sub> = OCH<sub>2</sub>CH<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>Cl-p, R<sub>2</sub> = Pr) and II (R = H, CH<sub>2</sub>Ph) were prepared. Thus, 2.7 g 4-oxo-4H-1-benzopyran-2-carbonyl chloride was treated with 1.3 g 5-amino-1-methyltetrazole to give 1.2 g I (R = Me, R<sub>1</sub> = R<sub>2</sub> = H).


IT 53542-83-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, with aminotetrazoles)

RN 53542-83-9 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 5,5'-[[2-(formyloxy)-1,3-propanediyl]bis(oxy)]bis[4-oxo- (9CI) (CA INDEX NAME)




IT 5112-47-0 42047-74-5

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with aminotetrazole)

RN 5112-47-0 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

INDEX NAME)



L36 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1974:82666 HCAPLUS Full-text

DOCUMENT NUMBER: 80:82666

TITLE: Antiallergic 5-ethoxy-2-chromonecarboxylic acid derivatives

INVENTOR(S): Umio, Suminori; Ueda, Ikuo; Sato, Yoshinari; Matsuo, Masaaki; Nakaguti, Osamu; Kobayashi, Masakazu

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd.

SOURCE: Ger. Offen., 30 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2331138	A1	19740110	DE 1973-2331138	19730619 <--
JP 49020177	A	19740222	JP 1972-62626	19720621 <--
JP 49020179	A	19740222	JP 1972-63407	19720624 <--
JP 49024967	A	19740305	JP 1972-65573	19720629 <--
JP 56035670	B	19810819		

PRIORITY APPLN. INFO.: JP 1972-62626 A 19720621  
JP 1972-63407 A 19720624  
JP 1972-65573 A 19720629

OTHER SOURCE(S): CASREACT 80:82666

GI For diagram(s), see printed CA Issue.


AB Seventeen chromones [I, R = e.g. OEt, ONa, 4-(2-hydroxyethyl)-1-piperazinyl, NHOH, or NHNH<sub>2</sub>; R<sub>1</sub> = e.g. Q with n = 0 or 1, EtO, Me<sub>2</sub>CHO, 3-Me<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>O, 4-AcNH-C<sub>6</sub>H<sub>4</sub>O, or PhO] or their hydrochlorides or maleates were prepared and used as antiallergics, especially in the treatment of asthma. Thus, reaction of the phenols II with (EtO<sub>2</sub>C)<sub>2</sub> gave I (R = OEt), which optionally were hydrolyzed to give I (R = ONa). Reaction of I (R = Cl) with piperazines gave I (R = 4-substituted 1-piperazinyl) and of I (R = OEt) with NH<sub>2</sub>OH or N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O gave I (R = NHOH or NHNH<sub>2</sub>, resp.).


IT 52426-46-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 52426-46-7 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo-5-(2-phenoxyethoxy)- (9CI) (CA INDEX NAME)





RN 42047-74-5 HCAPLUS  
 CN 4H-1-Benzopyran-2-carbonyl chloride, 5-(3-methylbutoxy)-4-oxo-8-(2-propenyl)- (9CI) (CA INDEX NAME)



L36 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1974:520460 HCAPLUS Full-text  
 DOCUMENT NUMBER: 81:120460  
 TITLE: Organic salts of chromone-2-carboxylic acids  
 INVENTOR(S): Tronche, Pierre A.  
 PATENT ASSIGNEE(S): Ferlux  
 SOURCE: U.S., 5 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3816470	A	19740611	US 1972-256614	19720524 <--
GB 1292826	A	19721011	GB 1969-1292826	19691103 <--
BE 743358	A	19700618	BE 1969-743358	19691218 <--
PRIORITY APPLN. INFO.:			US 1968-780223	A2 19681129
			FR 1968-179086	A 19681219
			US 1969-878896	A3 19691121

OTHER SOURCE(S): MARPAT 81:120460

GI For diagram(s), see printed CA Issue.

AB Chromonecarboxylic acid derivs. I [R = OH.NH<sub>2</sub>Et<sub>2</sub>, R<sub>1</sub> = H, 6-Cl, 7-Me; R = OH.NHMe<sub>2</sub>, OH.NHBu<sub>2</sub>, OH.NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>Ph, OH.NH<sub>2</sub>CH<sub>2</sub>Ph, OH.morpholine, OH.piperidine, OH.N-methylpiperazine, OH.cyclohexylisopropylamine, OH.2-aminopyridine, OH.papaverino, NHC<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H, NHC<sub>6</sub>H<sub>3</sub>(OH)CO<sub>2</sub>H-3,4, 2-pyridylamino, NHC<sub>6</sub>H<sub>4</sub>OH-p, NHNHPh, piperazinoethoxy, 2-carbamoylcyclohexyloxy, R<sub>1</sub> = H] were prepared and showed vitamin P activity. Thus, o-HOC<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>Me was treated with (EtO<sub>2</sub>C)<sub>2</sub> and NaOMe to give o-HOC<sub>6</sub>H<sub>4</sub>COCH<sub>2</sub>COCOC<sub>2</sub>Et, which was dehydrated to I (R = OH, R<sub>1</sub> = H) and treated with NH<sub>2</sub>Et. In the trypan blue test 40 mg/kg orally in rats I (R = OH.NH<sub>2</sub>Et<sub>2</sub>, R<sub>1</sub> = H) increased the time required for blue spots to appear by 88-109%. The compound was also analgesic in the light beam test at 400-800 mg/kg orally in mice. Its oral LD<sub>50</sub> in mice was >5 g/kg.

IT 5112-47-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, with p-aminophenol)

RN 5112-47-0 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 4-oxo- (6CI, 7CI, 8CI, 9CI) (CA



L36 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1968:95623 HCAPLUS Full-text

DOCUMENT NUMBER: 68:95623

TITLE: Compounds related to 2,4-dichlorophenoxyacetic acid and its derivatives

AUTHOR(S): Barrio, Jorge R.

CORPORATE SOURCE: Univ. Buenos Aires, Buenos Aires, Argent.

SOURCE: Journal of Medicinal Chemistry (1968), 11(2), 374-5

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 68:95623

GI For diagram(s), see printed CA Issue.


AB 2-Carboxy-6,8-dichloro- $\gamma$ -chromone (I) and its esters and amides were prepared. The Fries rearrangement of 2,4-dichlorophenyl acetate gave 3,5-dichloro-2-hydroxyacetophenone, which was treated with di-Et oxalate and NaOEt and then with HOAc-HCl to give I. None of the compds. showed any phytohormonal activity.

IT 17892-56-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 17892-56-7 HCAPLUS

CN 4H-1-Benzopyran-2-carbonyl chloride, 6,8-dichloro-4-oxo- (8CI) (CA INDEX NAME)



=> fil stng

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
63.80	541.44

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-8.25	-24.75

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 19:00:52 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.02	542.46

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-24.75

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 19:10:49 ON 19 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6  
DICTIONARY FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\346xi.str



chain nodes :  
1 2 3 4 6  
chain bonds :  
1-2 2-3 2-6 3-4  
exact/norm bonds :  
1-2 2-3 2-6 3-4

G1:Hy, Ph, o-C<sub>6</sub>H<sub>4</sub>, m-C<sub>6</sub>H<sub>4</sub>, p-C<sub>6</sub>H<sub>4</sub>, PhO, n-Bu, i-Bu, s-Bu, t-Bu

Match level :


1:CLASS 2:CLASS 3:CLASS 4:CLASS 6:CLASS

L37 STRUCTURE UPLOADED

=> d l37

L37 HAS NO ANSWERS

L37 STR



G1 Hy, Ph, o-C<sub>6</sub>H<sub>4</sub>, m-C<sub>6</sub>H<sub>4</sub>, p-C<sub>6</sub>H<sub>4</sub>, PhO, n-Bu, i-Bu, s-Bu, t-Bu

Structure attributes must be viewed using STN Express query preparation.

=> s l37 sss sam

SAMPLE SEARCH INITIATED 19:11:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3650 TO ITERATE

54.8% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 69377 TO 76623

PROJECTED ANSWERS: 3953 TO 5829

L38 50 SEA SSS SAM L37

=> d l38

L38 ANSWER 1 OF 50 REGISTRY COPYRIGHT 2006 ACS on STN

RN 910547-45-4 REGISTRY

ED Entered STN: 17 Oct 2006


CN Benzenecarboximidamide, 4,4'-(2,5-pyridinediyl)bis[N-hydroxy- (9CI) (CA INDEX NAME)

MF C19 H17 N5 O2

CI COM

SR CA

LC STN Files: CA, CAPLUS




\*\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d scan


```
L38 50 ANSWERS  REGISTRY  COPYRIGHT 2006 ACS on STN
IN  Benzenecarboximidamide, 4,4'-(2,5-pyridinediyl)bis[N-hydroxy- (9CI)
MF  C19 H17 N5 O2
CI  COM
```



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

```
L38 50 ANSWERS   REGISTRY   COPYRIGHT 2006 ACS on STN
IN  Acetic acid, [4-[(aminoacetyl)amino]-2-[[[4-chloro-2-[[[4-
    [(hydroxyamino)iminomethyl]phenyl]amino]carbonyl]phenyl]amino)methyl]-6-(1-
    methylethoxy)phenoxy]- (9CI)
MF  C28 H31 Cl N6 O7
CI  COM
```




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN [1,1'-Biphenyl]-4-carboximidamide, 4'-heptyl-N-hydroxy- (9CI)  
MF C20 H26 N2 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, N-hydroxy-4-[3-[4-[2-methyl-5-(1-methylethyl)-4-thiazolyl]phenoxy]propoxy]- (9CI)  
 MF C23 H27 N3 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 3-Pyridinecarboxamide, N-[5-ethyl-4-[4-[[5-[4-[(hydroxyamino)iminomethyl]phenoxy]pentyl]oxy]phenyl]-2-thiazolyl]- (9CI)  
 MF C29 H31 N5 O4 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, 4-[[5-[4-(2-amino-4-thiazolyl)phenoxy]pentyl]oxy]-N-hydroxy- (9CI)  
 MF C21 H24 N4 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Benzenecarboximidamide, 4-[[5-[4-(2-ethyl-4-thiazolyl)phenoxy]pentyl]oxy]-  
N-hydroxy- (9CI)

MF C23 H27 N3 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Thieno[2,3-c]pyridine-2-carboximidamide, 4-([1,1'-biphenyl]-4-ylamino)-N-  
hydroxy- (9CI)

MF C20 H16 N4 O S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN


IN 1H-1,2,4-Triazole-1-acetamide,  $\alpha$ -ethoxy-N-[[4-  
[(hydroxyamino)iminomethyl]phenyl]methyl]-3-phenyl- (9CI)

MF C20 H22 N6 O3





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1H-Indole-7-carboximidamide, N-hydroxy-3-[[4-(1-isoquinolinyl)-1-piperazinyl]oxoacetyl]-4-methoxy- (9CI)  
 MF C25 H24 N6 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Acetamide, N-[[[(5S)-3-[4-[4-[6-[4-[(Z)-amino(hydroxyimino)methyl]phenyl]-1-oxo-5-hexynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 MF C29 H33 F N6 O5  
 CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1-Piperidinecarboximidamide, 4-[[[(3,5-dimethyl-2-pyridinyl)methyl][(3-phenyl-2-pyridinyl)methyl]amino]-N-hydroxy- (9CI)  
 MF C26 H32 N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Pyridinium, 3-[(hydroxyamino)iminomethyl]-1-[[2-[[[4-




methoxyphenyl)methoxy]carbonyl]-8-oxo-7-[[[(triphenylmethoxy)imino][2-  
 [(triphenylmethyl)amino]-4-thiazolyl]acetyl]amino]-5-thia-1-  
 azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI)

MF C65 H55 N8 O7 S2

CI COM

Absolute stereochemistry.

Double bond geometry as shown.



L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN


IN Acetic acid, [[(1R)-1-(cyclohexylmethyl)-2-[(2S)-2,5-dihydro-2-[[[4-  
 [(hydroxyamino)iminomethyl]-2-thiazolyl]methyl]amino]carbonyl]-1H-pyrrol-1-  
 yl]-2-oxoethyl]imino]-, ethyl ester (9CI)

MF C23 H32 N6 O5 S

CI COM

Absolute stereochemistry.

Double bond geometry unknown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN 1H-Indole-3-carboximidamide, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-N-  
 hydroxy- (9CI)


MF C18 H18 Cl N3 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L38 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, N-hydroxy-4-(hydroxyamino)-  
 7-(2-C-methyl-β-D-ribofuranosyl) - (9CI)  
 MF C13 H18 N6 O6

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

2.78	545.24
------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00	-24.75
------	--------

FILE 'STNGUIDE' ENTERED AT 19:11:59 ON 19 DEC 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
 AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

0.42	545.66
------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
------------	-------

CA SUBSCRIBER PRICE

ENTRY	SESSION
0.00	-24.75

FILE 'REGISTRY' ENTERED AT 19:15:58 ON 19 DEC 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6  
DICTIONARY FILE UPDATES: 18 DEC 2006 HIGHEST RN 915867-78-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\346xii.str



chain nodes :

1 2 3 4 6

chain bonds :

1-2 2-3 2-6 3-4

exact/norm bonds :

1-2 2-3 2-6 3-4

G1: Ph, o-C<sub>6</sub>H<sub>4</sub>, m-C<sub>6</sub>H<sub>4</sub>, p-C<sub>6</sub>H<sub>4</sub>, PhO, Hy

Match level :


1:CLASS 2:CLASS 3:CLASS 4:CLASS 6:CLASS

L39 STRUCTURE UPLOADED

=> d l39

L39 HAS NO ANSWERS

L39 STR



G1 Ph,o-C<sub>6</sub>H<sub>4</sub>,m-C<sub>6</sub>H<sub>4</sub>,p-C<sub>6</sub>H<sub>4</sub>,PhO,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l39 sss sam

SAMPLE SEARCH INITIATED 19:16:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3650 TO ITERATE

54.8% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 69377 TO 76623  
PROJECTED ANSWERS: 3953 TO 5829


L40 50 SEA SSS SAM L39

=> d scan

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Benzenecarboximidamide, 4-[[5-[4-[5-(2-chloroethyl)-2-(dimethylamino)-4-thiazolyl]phenoxy]pentyl]oxy]-N-hydroxy- (9CI)


MF C25 H31 Cl N4 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10


L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Thieno[2,3-c]pyridine-2-carboximidamide, 4-([1,1'-biphenyl]-4-ylamino)-N-hydroxy- (9CI)  
MF C20 H16 N4 O S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenecarboximidamide, 4-(aminomethyl)-N-hydroxy-, bis(trifluoroacetate) (salt) (9CI)  
MF C8 H11 N3 O . 2 C2 H F3 O2

CM 1




CM 2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenecarboximidamide, N-hydroxy-2-(8-phenyl-1H-imidazo[4,5-c]quinolin-1-

yl) - (9CI)  
MF C23 H17 N5 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetic acid, [2-[[[4-chloro-2-[[[4-[(hydroxyamino)iminomethyl]phenyl]amino]carbonyl]phenyl]amino]methyl]-4-[[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]-6-(1-methylethoxy)phenoxy]-, 1,1-dimethylethyl ester (9CI)  
MF C37 H47 Cl N6 O9




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenecarboximidamide, 4-[[5-[4-(2-amino-4-thiazolyl)phenoxy]pentyl]oxy]-N-hydroxy- (9CI)  
MF C21 H24 N4 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetic acid, [2-chloro-4-[[1,3-dihydro-5-[(hydroxyamino)iminomethyl]-1-oxo-2H-isoindol-2-yl]acetyl]-3-hydroxyphenoxy]-, ethyl ester (9CI)  
MF C21 H20 Cl N3 O7




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Pyridinium, 2-[amino(hydroxyimino)methyl]-1-methyl-, (Z)- (9CI)  
 MF C7 H10 N3 O  
 CI COM




L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, 4,4'-[1,7-heptanediylbis(oxy)]bis[N-hydroxy- (9CI)  
 MF C21 H28 N4 O4  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, N-hydroxy-4-[3-[4-[2-methyl-5-(1-methylethyl)-4-thiazolyl]phenoxy]propoxy]- (9CI)  
 MF C23 H27 N3 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenecetic acid, 3,5-diethoxy- $\alpha$ -[[4-[(hydroxyamino)iminomethyl]phenyl]amino]-, methyl ester (9CI)  
MF C20 H25 N3 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):40


L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzenecarboximidamide, 3-[[[(2-amino-4-phenyl-1H-imidazol-1-yl)imino]methyl]-N-hydroxy- (9CI)  
MF C17 H16 N6 O  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 1H-Indole-3-carboximidamide, 1-[2-(4-chloro-3-methylphenoxy)ethyl]-N-hydroxy- (9CI)  
MF C18 H18 Cl N3 O2






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Acetic acid, [4-[(aminoacetyl)amino]-2-[[[4-chloro-2-[[[4-  
 [(hydroxyamino)iminomethyl]phenyl]amino]carbonyl]phenyl]amino]methyl]-6-(1-  
 methylethoxy)phenoxy]- (9CI)  
 MF C28 H31 Cl N6 O7  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, N-hydroxy-4-[[5-[4-[5-(methoxymethyl)-2-methyl-4-  
 thiazolyl]phenoxy]pentyl]oxy]- (9CI)  
 MF C24 H29 N3 O4 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, 4-(1,3-dioxolan-2-yl)-N-hydroxy- (9CI)  
 MF C10 H12 N2 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Pyridinium, 3-[(hydroxyamino)iminomethyl]-1-[[2-[[4-methoxyphenyl)methoxy]carbonyl]-8-oxo-7-[[[(triphenylmethoxy)imino][2-[(triphenylmethyl)amino]-4-thiazolyl]acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl]-, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI)  
 MF C65 H55 N8 O7 S2  
 CI COM

Absolute stereochemistry.  
 Double bond geometry as shown.




L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN  $\beta$ -D-Psicopyranose, 3-C-[(hydroxyamino)iminomethyl]-1,2:4,5-bis-O-(1-methylethylidene)-, 3-benzoate (9CI)  
 MF C20 H26 N2 O8




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, N-hydroxy-4-[[2-[[4-[2-methyl-5-(1-methylethyl)-4-thiazolyl]phenoxy]methyl]phenyl]methoxy]- (9CI)  
 MF C28 H29 N3 O3 S





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, N-hydroxy-4-[[5-[4-(2-methyl-4-thiazolyl)phenoxy]pentyl]oxy]- (9CI)  
 MF C22 H25 N3 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Acetamide, N-[[[(5S)-3-[4-[4-[6-[4-[(Z)-amino(hydroxyimino)methyl]phenyl]-1-oxo-5-hexynyl]-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 MF C29 H33 F N6 O5  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 3-Pyridazinecarboxylic acid, 4-amino-1,6-dihydro-5-  
[(hydroxyamino)iminomethyl]-1-(4-methoxyphenyl)-6-oxo-, ethyl ester (9CI)  
MF C15 H17 N5 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

```
L40 50 ANSWERS   REGISTRY   COPYRIGHT 2006 ACS on STN
IN  Acetic acid, [4-[(aminoacetyl)amino]-2-[[[4-chloro-2-[[[4-
    [(hydroxyamino)iminomethyl]phenyl]amino]carbonyl]phenyl]amino]methyl]-6-(1-
    methylethoxy)phenoxy]-, ethyl ester (9CI)
MF  C30 H35 Cl N6 O7
CI  COM
```




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, 4-[[5-[4-[5-ethyl-2-(propylamino)-4-thiazolyl]phenoxy]pentyl]oxy]-N-hydroxy- (9CI)  
 MF C26 H34 N4 O3 S




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1H-1,2,4-Triazole-1-acetamide,  $\alpha$ -ethoxy-N-[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]-3-phenyl- (9CI)  
 MF C20 H22 N6 O3




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Pyridinium, 1,1'-(1,3-propanediyl)bis[4-[(hydroxyamino)iminomethyl]- (9CI)  
 MF C15 H20 N6 O2  
 CI COM




L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2-Butenamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-fluoro-  
 3-[3-[(hydroxyamino)iminomethyl]phenyl]-, (2E)- (9CI)  
 MF C23 H20 F2 N4 O4 S

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, 3-[[4-(2-fluoroethyl)-1,1-dioxido-4H-1,2,4-  
 benzothiadiazin-7-yl]oxy]-N-hydroxy- (9CI)  
 MF C16 H15 F N4 O4 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, 4-[[5-[4-(2-ethyl-4-thiazolyl)phenoxy]pentyl]oxy]-  
 N-hydroxy- (9CI)  
 MF C23 H27 N3 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 3-Pyridinecarboximidamide, 2-chloro-N-hydroxy-6-(trifluoromethyl)- (9CI)  
 MF C7 H5 Cl F3 N3 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzeneacetamide,  $\alpha$ -(cyclopentylmethyl)-N-[5-  
 [(hydroxyamino)iminomethyl]pyrazinyl]-4-(methylsulfonyl)-, ( $\alpha$ R)-  
 (9CI)  
 MF C20 H25 N5 O4 S


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN INDEX NAME NOT YET ASSIGNED

MF C4 H6 N6 O2 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 3-Pyridinecarboxamide, N-[5-ethyl-4-[4-[[5-[4-  
[(hydroxyamino)iminomethyl]phenoxy]pentyl]oxy]phenyl]-2-thiazolyl]- (9CI)  
MF C29 H31 N5 O4 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 6-Benzofurancarboximidamide, N-hydroxy-2-[4-[(hydroxyamino)iminomethyl]phenyl]- (9CI)  
MF C16 H14 N4 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Acetic acid, [[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl] [(2E)-3-[3-[(hydroxyamino)iminomethyl]phenyl]-2-propenyl]amino]sulfonyl]-, ethyl ester, hydrochloride (2:5) (9CI)  
MF C26 H35 N5 O5 S . 5/2 Cl H

Double bond geometry as shown.






●5/2 HCl

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 7H-Pyrrolo[2,3-d]pyrimidine-5-carboximidamide, N-hydroxy-4-(hydroxyamino)-  
 7-(2-C-methyl-β-D-ribofuranosyl)- (9CI)  
 MF C13 H18 N6 O6

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN [1,1'-Biphenyl]-4-carboximidamide, 4'-heptyl-N-hydroxy- (9CI)  
 MF C20 H26 N2 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, 4-[[5-[4-[5-butyl-2-(3-pyridinyl)-4-thiazolyl]phenoxy]pentyl]oxy]-N-hydroxy- (9CI)  
 MF C30 H34 N4 O3 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, 3-[(2,3-dihydro-5,5-dioxido-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazin-7-yl)oxy]-N-hydroxy- (9CI)  
 MF C17 H16 N4 O4 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Acetic acid, [[[1R]-1-(cyclohexylmethyl)-2-[(2S)-2,5-dihydro-2-[[[4-[(hydroxyamino)iminomethyl]-2-thiazolyl]methyl]amino]carbonyl]-1H-pyrrol-1-yl]-2-oxoethyl]imino]-, ethyl ester (9CI)  
 MF C23 H32 N6 O5 S  
 CI COM

Absolute stereochemistry.  
 Double bond geometry unknown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, 4,4'-(2,5-pyridinediyl)bis[N-hydroxy- (9CI)  
 MF C19 H17 N5 O2  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, 4-[[5-[4-[5-cyclopentyl-2-(propylamino)-4-thiazolyl]phenoxy]pentyl]oxy]-N-hydroxy- (9CI)  
 MF C29 H38 N4 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 2H-1,4-Benzoxazine-2-carboxylic acid, 4-ethyl-3,4-dihydro-7-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-2-methyl-3-oxo-, ethyl ester (9CI)  
 MF C22 H24 N4 O6




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1-Piperidinecarboximidamide, 4-[[[(3,5-dimethyl-2-pyridinyl)methyl][(3-phenyl-2-pyridinyl)methyl]amino]-N-hydroxy- (9CI)  
 MF C26 H32 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 3-Pyridinecarboximidamide, N-hydroxy-6-[5-[3-[(hydroxyamino)iminomethyl]phenyl]-2-furanyl]- (9CI)  
 MF C17 H15 N5 O3  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzamide, N-[6-[(hydroxyamino)iminomethyl]-3-pyridinyl]-5-methyl-2-nitro- (9CI)  
 MF C14 H13 N5 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzenecarboximidamide, 4-[[5-[[4-[[5-(cyclopentylmethyl)-2-ethyl-4-thiazolyl]phenoxy]pentyl]oxy]-N-hydroxy- (9CI)  
 MF C29 H37 N3 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN 1H-Indole-7-carboximidamide, N-hydroxy-3-[[4-(1-isoquinolinyl)-1-piperazinyl]oxoacetyl]-4-methoxy- (9CI)  
 MF C25 H24 N6 O4




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2-Furancarboximidamide, 5-(2-aminophenyl)-N-hydroxy- (9CI)  
MF C11 H11 N3 O2  
CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L40 50 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN 2-Thiophenecarboximidamide, 3-bromo-N-hydroxy- (9CI)  
MF C5 H5 Br N2 O S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

0.88	546.54
------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00	-24.75
------	--------

FILE 'STNGUIDE' ENTERED AT 19:17:00 ON 19 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 19, 2006 (20061219/UP).

=> fil stng

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

1.20	547.74
------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00	-24.75
------	--------